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Abstract 
Antimicrobial peptides (AMPs) are part of the innate immune system that 
is widely distributed in nature, acting as a defense mechanism against invading 
microorganisms.  AMPs have potent antimicrobial activity against a range of 
microorganisms including fungi, bacteria, and viruses.  In view of growing 
multidrug resistance, AMPs are increasingly being viewed as potential 
therapeutic agents with a novel mechanism of action.  Mastoparan is a natural, 
highly positively charged AMP derived from the venom of wasps.  It was 
originally of interest based on its inherent mast cell degranulation activity.  
Previously, mastoparan has been shown to exhibit antimicrobial activity in vitro; 
however, these studies have been limited in scope.  Here we hypothesize that 
mastoparan possess the capacity to be a potent broad-spectrum antibacterial 
agent including activity against multidrug resistant bacteria.   
We examined the scope of antibacterial activity exhibited by mastoparan 
using a variety of antimicrobial susceptibility tests and have utilized a bacterial 
skin infection (Staphylococcus aureus) model to determine the potential of 
mastoparan to serve as a therapeutic agent.  We tested mastoparan against four 
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Gram-positive clinical isolates (e.g., Staphylococcus aureus, and Enterococcus 
faecium), nine Gram-negative clinical isolates (e.g., Escherichia coli, Pseudomonas 
aeruginosa, and Burkholderia cepacia), and four multidrug resistant clinical isolates 
(e.g., MRSA, ESBL Escherichia coli, and ESBL Klebsiella  pneumonia).  These studies 
reveal that mastoparan exhibits broad-spectrum activity against both Gram-
negative (MIC: 1.9 – 125 μg/ml) and Gram-positive (MIC: 15.6 – 125 μg/ml) 
bacteria and against multidrug resistant bacteria (MIC: 7.8 – 125 μg/ml).  We also 
demonstrated that mastoparan disrupts the bacterial membrane, exhibits fast 
acting antibacterial activity, and is highly effective against both multiplying and 
non-multiplying bacteria.  Furthermore, we have shown that mastoparan 
demonstrates efficacy as a topical antimicrobial agent reducing lesion size by up 
to 79% and the amount of bacteria recovered from skin lesions by up to a 98% 
reduction.  Based on these results we conclude that mastoparan is a highly 
effective antibacterial agent and is therefore a potential alternative to currently 
antibiotics.  Mastoparan offers a promising new therapeutic option for treating 
bacterial infections. 
. 
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Chapter 1:  Introduction 
1.1 Bacterial Infections 
 Bacteria are a major cause of human death and disease and are responsible 
for infections such as tuberculosis, pneumonia, tetanus, typhoid, cholera, and 
foodborne illness.  The World Health Organization (WHO) lists lower respiratory 
infections (pneumonia, tuberculosis and bronchitis) and diarrhoeal diseases 
(most commonly caused by Escherichia coli and rotavirus) as the top two leading 
causes of death in low-income countries and the top five causes of death 
worldwide [1].  Infection occurs when bacteria in the environment as a 
component of either the indigenous microbiota or as exogenous organisms 
invade the host.   
Bacteria are classified as either Gram-positive or Gram-negative, broadly 
based on the structural differences of their cell membrane and the effects of these 
structural differences on the outcome of the Gram stain test established by Hans 
Christian Gram.  Gram-positive bacteria have a thick peptidoglycan layer and a 
single membrane, while Gram-negative bacteria contain both an inner and outer 
membrane.  Bacteria multiply at a rapid rate with generation times varying from 
several minutes to greater than 24 hours.  This rapid generation typically occurs 
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via binary fission and can select for beneficial, spontaneous mutations that 
account for rapid evolutionary adaptation.  These adaptations allow bacteria to 
utilize a variety of nutritional sources, which contributes to their ability to 
occupy habitats where few other forms of life can exist.  Bacteria, which can 
infect humans, animals and plants, can develop a range of different relationships 
with a host including parasitic, free-living, and mutualistic.  Bacteria have been 
known to infiltrate our bodies, food (e.g., crops and domesticated livestock), and 
water supply.  Their metabolic diversity allows them to persist in a range of 
different habitats.   
While bacteria are a major cause of disease, not all bacteria are pathogenic.  
Non-pathogenic bacteria play a vital role in ecosystems and in human society 
such as in waste breakdown, drug production, and environmental 
bioremediation.  As a natural host for bacteria, humans possess a microbiome 
made up of bacteria in places such as the gastrointestinal tract, mucosal surfaces 
and skin.  The bacteria that comprise the human microbiota are typically 
beneficial or harmless; however, a pathogenic association can develop if bacteria 
numbers grow beyond their typical ranges, the host has a compromised immune 
system, or bacteria are able to populate atypical or vulnerable areas of the body 
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[2-5].  In addition to these opportunistic pathogens, there are also obligate 
pathogens, which in contrast, are not typically a component of the normal 
microbiota and are only able to grow and reproduce within the cells of other 
organisms.  These types of pathogens cause diseases such as chlamydia 
(Chlamydia trachomatis) and typhus (Rickettsia bacteria).  Bacterial infections result 
from an imbalance of bacterial virulence and host defense mechanisms.  Natural 
selection usually favors a predominance of less virulent microorganisms as it is 
typically more beneficial for bacteria to multiply rather than cause disease [6].  
Death or severe impairment of the host caused by pathogenic infections 
compromises the survival of the infecting microbe, therefore; it is in the best 
interest of the bacteria to thrive in the host without causing significant damage 
[7, 8]. 
Approaches to treat bacterial infections constitute the major emphasis of 
this dissertation.  Here we propose the use of an antimicrobial and immune 
stimulatory peptide as a potential antimicrobial agent against bacterial infections.  
The subsequent sections of this chapter describe the attributes of pathogenic 
bacteria, the host-pathogen relationship created during infection, the 
mechanisms by which microorganisms are able to cause infections, and ways 
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(e.g., using wasp venom antimicrobial peptides) in which we can treat bacterial 
infections.  Focus is also given to the emergence of resistant bacterial pathogens 
and the global health problem that this presents. 
1.1.1 Bacterial host-pathogen interaction in humans 
 The manifestation of the host-pathogen interaction depends on the 
interplay of bacteria virulence factors and the host response.  The skin and 
mucosal surfaces act as a physical and chemical barrier, providing the first line of 
defense against colonization by bacterial pathogens [9].  In healthy individuals, 
the cellular and humoral mechanisms of the host are capable of clearing the 
bacteria that are able to penetrate these barriers.  However, in individuals with a 
defective immune response, even less virulent bacteria are able to colonize and 
cause frequent, recurring infections.  Elderly individuals and infants are 
especially susceptible to infections due to immune systems that are weakened or 
have not been fully developed [10-14].  Furthermore, the indigenous bacteria 
microbiota found on the skin and at mucosal sites, also functions as a line of 
defense against the colonization of exogenous bacteria [4].  Indigenous bacteria 
produce proteins, metabolites, and end products that function as specific and 
nonspecific antagonist against exogenous bacteria.  If a bacterial pathogen is able 
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to overcome this first line of defense and breaches an anatomical barrier, then the 
potential for colonization is increased. 
 Colonization is the first stage of an infection and usually occurs in host 
tissues that are in contact with the external environment [15].  Once bacteria have 
penetrated the skin or mucosal surfaces, the host employs several mechanisms of 
growth restriction, such as cellular defenses (e.g., phagocytosis and 
inflammation) [16-18].  The innate immune system defends against pathogens by 
producing antibacterial enzymes (e.g., lysozyme) and rapid localization of 
macrophages and neutrophils to engulf and kill foreign cells [19-24].  The 
inflammatory response serves as a means to recruit cells (e.g., neutrophils, 
macrophages, and lymphocytes) and defensive components (e.g., antibodies, and 
complement) to the site of invasion [25, 26].  In addition to the activation of the 
innate immune system, the body may also utilize mechanisms of adaptive 
immunity to detect and attack bacterial pathogens.  The adaptive immune 
system exhibits immunological memory involving antibody-mediated immunity 
(AMI) and cell-mediated immunity (CMI) that allows the body to react quickly if 
exposed to the same organism in the future.  This systemically-acquired response 
serves to inhibit future invasion and damage and includes defense mechanisms 
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such as interleukin production by T cells and the production of circulating 
antibodies by plasma cells [27, 28].  Overall, the host utilizes a variety of 
resistance mechanisms to defend against bacterial pathogens; however, the 
pathogen also employs a number of strategies that allow for survival in the 
presence of these host defense mechanisms. 
In order for a bacterial pathogen to establish an infection, several things 
must occur.  The pathogen must be able to attach and enter the body, evade the 
host defenses, multiply to significant numbers, and transmit the infection so that 
the cycle can continue.  Once inside of the host, bacteria utilize several 
mechanisms that allow them to evade the host defenses.  Many bacteria can be 
encapsulated in mimics of host matrices allowing them to go unrecognized by 
phagocytes and protect them from phagocytosis [17, 29].  Gram-negative bacteria 
produce lipopolysaccharide endotoxins that can provide protection against host 
membrane attack complexes and can cause potentially lethal biologic effects (e.g., 
fever, lethal shock and sepsis) [30, 31].  Both Gram-negative and Gram-positive 
bacteria secrete exotoxins (e.g., cytotoxins, neurotoxins, and enterotoxins), 
extremely toxic substances that cause damage to the host [32].  The ability of 
bacterial pathogens to overcome and evade the extensive capabilities of the host 
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defense mechanisms serves as evidence that bacterial virulence is a highly 
sophisticated process. 
The many factors that contribute to the outcome of a host-pathogen 
interaction, and the relationship between bacteria and the host, force their 
individual evolution to be inevitably linked.  Much of the current knowledge 
about the human immune system has come through the investigation of host-
pathogen interactions that occur for successful versus unsuccessful pathogens.  
As understanding of the intricacies of the immune system increases, there is a 
corresponding increase in the understanding of bacterial mechanisms that 
subvert the immune response.  Additionally, increased understanding of the 
host-pathogen relationship on a molecular level also provides valuable insight on 
pathogens and pathogenicity.  This information is useful in designing novel 
ways to counter bacterial infections.  The infectious disease problem is a growing 
public health issue.  Understanding of the host-pathogen interaction is pivotal in 
developing future technologies that increase host resistance to bacterial 
pathogens. 
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1.1.2 Bacterial skin infections 
Bacterial skin infections are responsible for a variety of debilitating 
chronic clinical skin conditions including impetigo, cellulitis, 
folliculitis/furunculosis, abscesses, and ulcers [33-35].  Gram-positive bacteria 
(e.g., Staphylococcus and Streptococcus) characteristically cause bacterial skin 
infections; however, Gram-negative organisms (e.g., Pseudomonas) may also 
cause some skin infections.  These infections have become a significant public 
health problem as they result in over 11 million outpatient and emergency room 
visits and ~500,000 hospitalizations per year in the United States [33].    
The skin, which harbors a diverse array of bacteria that are typically 
nonpathogenic, serves an important role as a barrier at the host-environment 
interface.  Initial colonization of the skin by bacteria occurs in the birth canal, and 
the normal microbiota is established within 48 hours after birth [36, 37].  It is 
estimated that one square centimeter of human skin is home to 1,000 – 10,000 
different bacteria organisms [38-40].  Susceptibility to infection occurs when the 
skin barrier is breached, especially in situations such as burns, surgical wounds, 
and cuts.  Treatment of these infections has been complicated by the widespread 
emergence of antimicrobial resistant strains such as methicillin-resistant 
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Staphylococcus aureus (MRSA) [41-45].  Even in instances where appropriate 
antimicrobials are applied, they are largely ineffective because many of the 
bacteria are in stationary phase and are typically not affected by antimicrobial 
agents [46-50].  As a result of these limitations in therapy, skin infections remain 
highly debilitating, especially in immunocompromised individuals.  The studies 
outlined in this dissertation investigate an approach to potentially treat bacterial 
skin infections.   
1.2 Antimicrobial Agents 
 In addition to the natural host immune response to bacterial pathogens, 
there are also antimicrobial agents that assist in the fight against these pathogens.  
The therapeutic use of antimicrobial agents has had a powerful impact on the 
treatment of infectious diseases.  Ancient cultures used antimicrobial agents, 
even without understanding the underlying cause of the antimicrobial properties 
of these substances.  Early Egyptians (around 1550 BC) used a mixture of honey, 
lard, and lint to dress wounds, and it is now known that honey contains 
hydrogen peroxide, which has antibacterial properties [51-53].  Other ancient 
civilizations used moldy bread, soil and plants to treat infected wounds [53, 54].  
The therapeutic nature of these substances was most likely due to metabolites 
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and chemicals serving as raw forms of antibiotics, and these cultures believed 
that these remedies influenced the spirits or Gods associated with the illnesses 
[52]. 
 Towards the end of the 19th century, the introduction of the germ theory of 
disease ushered in improvements in the defense against bacterial diseases by 
expanding understanding of the causes of disease and proposing that 
microorganisms are at the root of many infectious diseases [55-58].  This led to 
increased research into effective ways to remedy microbial infection.  One such 
finding by E. de Freudenreich in 1888, was the use of a blue pigment from 
Bacillus pyocyaneus which demonstrated antimicrobial activity against bacteria 
and was later named “pyocyanase” by Rudolf Emmerich and Oscar Loew [52].  
The discovery of penicillin by Alexander Fleming is stated to have initiated the 
modern era of antimicrobial agents.  Fleming noticed that a fungus from the 
Penicillium genus inhibited the growth of bacteria in culture dishes, Ernst Chain 
and Howard Florey later purified this antibiotic [59-62].  Penicillin came into 
clinical use in the 1940s and is renowned for saving the lives of many soldiers 
during World War II. 
  
11 
In the decades following these discoveries scientist ushered in the golden 
age of antimicrobial development highlighted by the discoveries of 
chloramphenicol, tetracycline, streptomycin, and erythromycin.  By the 1960s, 
advances in fermentation techniques and medicinal chemistry strengthened 
progress and led to the attainment of a broader antimicrobial spectrum and 
higher antimicrobial activity.  Nevertheless, the development of antimicrobials 
with novel mechanisms of action has slowed in recent times, with the majority of 
recently introduced antimicrobials being modifications of previously discovered 
drugs [63, 64].  Infectious diseases continue to be a growing global issue with an 
increase in opportunistic infections, emerging and re-emerging infections, and 
resistant microorganisms. 
Antimicrobial agents are classified based on several different 
characteristics including their spectrum of activity and their bactericidal or 
bacteriostatic effect.  The spectrum of activity of an antimicrobial agent depends 
on the range of bacterial species that these agents are able to affect.  An 
antibacterial that has a broad spectrum of activity is effective against a wide 
range of both Gram-positive and Gram-negative bacteria (e.g., fluoroquinolones 
and tetracyclines).  A narrow spectrum antibacterial is only effective against 
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Gram-negative or Gram-positive bacteria (e.g., bacitracin, which is only effective 
against Gram-positive bacteria, and polymyxins, which are usually only effective 
against Gram-negative bacteria).  Additionally, antimicrobial agents are 
classified by their ability to cause actual death of bacteria (bactericidal effect) or 
simply inhibit or delay growth and replication (bacteriostatic effect).  Some 
antibacterial agents are both bactericidal and bacteriostatic depending on the 
state of the invading bacteria (e.g., log versus stationary phase), the duration of 
exposure, and the concentration [63, 65].  Bacteriostatic agents typically have a 
slower mechanism of action.  However, bacteriostatic agents can be 
advantageous since they require collaboration with the host immune system as 
normal defenses of the host are ultimately responsible for destroying the 
microorganism [52, 65].  Thus, bacteriostatic agents are not very effective in 
immunosuppressed or immunocompromised individuals. 
Antimicrobial agents are categorized as an antibiotic if it is a natural 
substance produced by microorganisms, a chemotherapeutic agent if it is 
chemically synthesized, and a semisynthetic if it is a hybrid substance that is 
produced from natural substances that have been modified by chemist [66].  
Overall, in order for an antimicrobial agent to be clinically useful it must exhibit 
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a range of beneficial characteristics: a broad spectrum of activity, nonallergenic, 
minimal toxicity and side effects, chemically stable, inexpensive and easy to 
produce, able to reach the site of infection, and improbable microbial resistance 
development.  Unfortunately, there is not a single agent that works best for all 
applications.  Nonetheless, knowledge of the characteristics exhibited by an ideal 
antimicrobial can be useful in the development of future antimicrobial agents.   
1.2.1 Antimicrobial agents’ mechanism of action 
In order for a bacterial infection to occur, bacterial cells must grow and 
divide, and this requires the bacteria to synthesize or incorporate many different 
biomolecules.  Efficacious antimicrobial agents have the ability to inhibit specific 
processes that are necessary for bacterial growth and/or division.  These 
mechanisms of action are based on the structure of the antimicrobial and their 
target site within the bacterial cell.   
The bacterial cell wall is critical for the life and survival of bacteria.  
Human and animal cells do not have cell walls; therefore, antimicrobial agents 
can selectively target the cell wall and only affect bacterial species.  As noted 
previously, bacteria are classified as Gram-positive or Gram-negative.  Both 
Gram-positive and Gram-negative bacterial cell walls contain peptidoglycan.  
  
14 
Antimicrobial agents that inhibit cell wall synthesis generally inhibit a step in the 
synthesis of bacterial peptidoglycan [67-70].  Examples of antimicrobials that 
inhibit bacterial cell wall synthesis are penicillins, cephalosporins, bacitracin, and 
vancomycin. 
The cell membrane plays an important role in separating the intracellular 
and extracellular environment of the cell and serves in regulating the flow of 
substances (e.g., water, ions and nutrients) in and out of the cell.  Cell 
membranes are composed of lipids, proteins, and lipoproteins.  Antimicrobial 
agents that inhibit cell membrane function and integrity usually cause 
disorganization of the structure of the membrane or loss of function.  If the 
integrity of the cell membrane is compromised, leakage of cell content (e.g., ions 
and macromolecules) can occur, leading to rapid cell death.  Both human and 
bacterial cells contain phospholipid cell membranes, and thus antimicrobial 
agents that interact with the cell membrane typically have a poor selective 
toxicity.  However, some structural differences between bacterial and human cell 
membranes exists and include the presence of lipopolysaccharides (LPS) on the 
outer membrane of Gram-negative bacteria [71, 72], and the lack of sterols 
(except in mycoplasmas) [73-75].  Examples of antimicrobials that disrupt the cell 
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membrane are polymyxins, which have specificity for the lipopolysaccharide 
molecule [76-79]. 
Bacterial cells depend on protein synthesis for multiplication and survival.  
Many therapeutic agents inhibit bacterial protein synthesis.  Protein synthesis 
inhibitors disrupt cellular metabolism, which inhibits growth and multiplication 
in bacteria.  Eukaryotic and prokaryotic ribosomes differ in size and in relation to 
the amino acid composition of the ribosomes, which confers specificity upon this 
class of antimicrobials [80, 81].  The major antimicrobial agents exploiting this 
mechanism of action are aminoglycosides, tetracyclines, chloramphenicol, and 
macrolides. 
Synthesis of DNA and RNA are key processes in all living organisms.  
Antimicrobial agents that inhibit nucleic acid synthesis exploit the differences 
that exist in relation to structure and sequence, between eukaryotes and 
prokaryotes.  Antimicrobial agents of this nature can work by binding bacteria-
specific components involved in replication and transcription of DNA (e.g., DNA 
or RNA polymerases), by binding directly to the DNA or RNA to prevent their 
function, or they can hinder the synthesis of nucleotides or interconversion.  
Bacterial organisms that are unable to replicate DNA or transcribe DNA into 
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RNA are compromised in their ability to multiply and survive.  Examples of 
antimicrobial agents that inhibit nucleic acid synthesis are quinolones and 
rifamycins.  Some antimicrobial agents specifically inhibit cellular processes that 
exist in the bacterium but not in the host.  Chemically, these inhibitors are 
analogous to bacterial metabolites or growth factors that are necessary for 
bacterial metabolism.  However, these mimics are unable to perform the 
metabolic function and competitively inhibit the function of the normal 
metabolite [82].   
Antimicrobial agents have the potential to affect both the host and the 
microorganism but most have a mechanism of action that specifically inhibits 
processes and structures that are only found in bacterial cells.  The therapeutic 
use of antimicrobial agents requires that we understand not only the 
pathogenesis of the infection but also the pharmacodynamics and efficacy of the 
drug.  The selection of an antimicrobial agent should ultimately be based upon 
the incorporation of the antibacterial activity of the agent with its pharmacologic 
properties. 
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1.2.2 Bacterial resistance to antimicrobial agents 
Antimicrobial substances are powerful therapeutic tools and have been 
critical in the global reduction of death and disease due to infectious diseases.  
Unfortunately, they have not eliminated bacterial diseases from human and 
animal populations and the development of antimicrobial resistant bacteria has 
significantly reduced their efficacy.  The World Health Organization defines 
antimicrobial resistance as the “resistance of a microorganism to an antimicrobial 
medicine to which it was previously sensitive” [83].  Antimicrobial resistant 
bacteria have a higher minimum inhibitory concentration (MIC) than what was 
originally required.  Multidrug resistant organisms are those that are resistant to 
more than one antimicrobial agent, typically from different classes.  
Antimicrobial resistant bacteria are able to survive and multiply in the presence 
of an antimicrobial agent due to some change in the population that abolishes the 
efficacy of the antimicrobial.   
Antimicrobial resistant pathogens represent a large public health and 
economic burden.  Individuals that are infected by antimicrobial resistant 
bacteria typically have prolonged illness, greater possibility of death, and an 
increased potential of spreading the resistant organism to others [84].   
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Antimicrobial resistant bacteria are responsible for increased cost of treatment 
and longer hospitalization, which burdens the entire health care system.  The 
Centers for Disease Control and Prevention (CDC) reports that these pathogens 
cost an estimated $21 - $34 billion a year in health care costs and $35 million in 
other societal costs [85, 86].  Each year approximately 2 million Americans (5%-
10% of all hospitalized patients) develop hospital-acquired infections which 
result in more than 95,000 deaths and the majority of these deaths are due to 
antimicrobial resistant pathogens [86, 87].  Of the bacteria causing infections in 
hospitals today, approximately 70% of them are resistant to at least one 
commonly used drug; given the current trend, it is suggested that within the next 
ten years we will no longer have effective treatments for the diseases associated 
with these pathogens [83, 88].  The Director-General of the World Health 
Organization spoke to the ensuing problem surrounding antimicrobial resistance 
in her keynote address at the 2012 “Conference on Combating Antimicrobial 
Resistance: Time for Action.”  The Director-General warned that if the present 
trend continues, then “things as common as strep throat or a child’s scratched 
knee could once again kill” and that “some sophisticated interventions, like hip 
replacements, organ transplants, cancer chemotherapy, and care of preterm 
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infants, would become far more difficult or even too dangerous to undertake” 
[89]. 
Antimicrobial resistance has been an issue since the start of the 
antimicrobial era [90, 91].  Soon after penicillin began to be widely used, it was 
discovered that some bacterial strains had developed resistance to this antibiotic 
[92].   With the development and introduction of each new class of antimicrobial 
agents came the emergence of resistant microorganisms.  This emergence is not 
surprising since pathogens, like all living organisms, are guided by natural 
selection.  Resistance development in bacteria is abetted by their ability to evolve 
rapidly, their short generation time and their capacity to exchange genetic 
information encoding for resistance in an inter- and intra- species fashion [93].  
Many bacterial organisms synthesize antibiotics, therefore, the genes for 
resistance development are ancient, given that these microbes have mechanisms 
to survive in the presence of the antimicrobials that they themselves produce [94-
96].  Penicillin-resistant bacteria were in the environment before penicillin was 
used therapeutically, and penicillinase was recovered from dried soil in dormant 
Bacillus licheniformis endospores [97, 98].  These naturally occurring resistance 
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genes can be transferred from nonpathogenic bacteria to those that cause disease 
[95]. 
Bacteria are very adept at mounting resistance to antimicrobial agents, 
and there are a number of mechanisms that have evolved to confer resistance.  
The basic mechanisms of resistance include inactivation or chemical modification 
of the antimicrobial, altered entry or active export of the antimicrobial from the 
cell, alteration of the target site for the antimicrobial, development of a resistant 
metabolic pathway, or acquisition of an enzyme in exchange for the sensitive one 
[99-101].  Bacteria can develop antimicrobial resistance as an inherent/natural 
property or as a secondarily acquired mechanism [96].  Bacterial cells that are 
able to survive the effects of an antimicrobial agent can then pass the resistant 
genes on to other bacterial cells via vertical or horizontal gene transfer [85, 102].  
Vertical transfer is the passage of resistance genes that result from chromosomal 
mutations from one generation to the next via DNA replication [96].  Horizontal 
gene transfer occurs via conjugation (direct transfer via cell-to-cell contact), 
transformation (via plasmids or transposons), or transduction (bacteriophage 
transfer) [96, 102].  Continued exposure to antimicrobials provides a selective 
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pressure that creates a situation in which the persisting bacteria are more likely 
to be resistant [85, 103]. 
Soon after the use of antimicrobial agents began, signs of resistance to 
these antimicrobials were observed.  These antimicrobial agents allowed us to 
cure some common infections and control outbreaks of infectious diseases.  
Nevertheless, this victory was premature and it is now evident that 
microorganisms are not only capable of mounting resistance at an alarming rate, 
but there is a rapid increase in multiple drug resistance as well.  This presents us 
with a frightening trend considering that most antimicrobials may no longer be 
effective for the generation to come, and common bacterial infections may once 
again become lethal.  The fight against these resistant pathogens continues, and 
long-term management of the increase in microbial resistance will require a 
change in both behavior as well as the evolutionary view of microbes to devise 
innovative ways to combat infections.  
1.2.3 Factors contributing to antimicrobial resistance 
Evolutionary pressure exerted by an antimicrobial drives resistance 
development and the spread of resistance amongst bacterial species.  In addition 
to understanding the scientific basis of resistance, it is also imperative to 
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understand the social and administrative practices that contribute to resistance 
emergence.  One major driving factor behind antimicrobial resistance is the 
misuse or overuse of antibiotics [83, 93].  Each time an individual utilizes an 
antimicrobial agent the sensitive bacteria are killed; however, the resistant 
organisms are able to survive and multiply.  An individual has a greater 
potential for antimicrobial resistance development for up to a year after taking a 
single dose of an antimicrobial agent [104].  Patient expectations, in which 
patients have come to expect to receive antimicrobial agents even when these 
drugs may not be effective, typically drive overuse.  One study reports that 
antibiotics were prescribed in 68% of acute respiratory tract infections even 
though they were unnecessary in 80% of these cases [104].  The use of 
antimicrobial agents against microorganisms to which they are ineffective such 
as viral infections (e.g., common cold and the flu) is a leading force in the 
emergence of resistance [85]. 
In some countries, antimicrobial agents are sold without a prescription, 
which also promotes resistance development due to misuse.  These drugs are 
typically poorly manufactured, counterfeit and lacking in full potency [93].  
Some additional behaviors driving antimicrobial resistance are failure to adhere 
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to the recommended dosing information (e.g., premature discontinuation, and 
ill-timed dosing), inability to afford the full course therapy, and poor hygiene 
[93, 105, 106].  Hospitals are also responsible for the emergence of resistance with 
a combination of immunocompromised patients, extensive antimicrobial use, 
invasive procedures and close proximity of patients [93].  This leads to the 
outcome of many hospital-acquired infections that are extremely resistant. 
The debate over the magnitude and nature of the antimicrobial resistance 
problem is riddled with controversy.  Many reports contend that the major cause 
of antimicrobial resistance is the abuse and misuse of antimicrobial agents [107-
110].  A move towards the judicious use of antimicrobials through optimal drug 
selection and appropriate dose and duration may slow the emergence of 
resistance development.  Regardless of the cause, human ingenuity has not 
outsmarted microorganisms, and resistance has become a global public health 
challenge. 
The Centers for Disease Control and Prevention estimates that 1 in 6 
Americans (approximately 48 million people) contract a foodborne illness each 
year, resulting in 128,000 hospitalizations and 3,000 deaths [111].  Bacteria (e.g., 
Salmonella, Escherichia coli, and Listeria), Toxoplasma or norovirus typically cause 
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foodborne illnesses and treatment usually requires antimicrobial agents [111, 
112].  Thus, antimicrobial resistance in foodborne pathogens is a major concern.  
Antimicrobial agents are intensively used in the food production industry to 
promote animal growth, protect animal resources from infection, minimize the 
increase in zoonotic bacteria into the environment and food chain, treat sick 
animals and contain epidemics that could result in loss of animal and human 
lives [112-116].  Additionally, the use of antimicrobials to promote animal growth 
came about after research showed improved growth in animals that received 
subtherapeutic amounts of antimicrobials [117, 118].  Soon after these 
experiments, the Food and Drug Administration (FDA) approved the use of 
antibiotics in livestock diets as a means of growth promotion and disease 
prevention [112, 119].  Approximately 40-70% of the total antimicrobial 
production in the United States is used in the livestock industry, and antibiotic 
use in animal husbandry represents the most abundant use of antimicrobials 
worldwide [93, 112, 120-122]. 
The use of antimicrobial agents in animals has many benefits.  
Nonetheless, along with these benefits comes a contribution to the increase in the 
emergence of antimicrobial resistance.  The non-therapeutic use of antibiotics as 
  
25 
a food additive to promote growth and prevent infections reduces drug efficacy 
and promotes the growth of antimicrobial resistant bacteria that can be 
subsequently transmitted to humans [112, 113, 123-128].  For instance, 
nonpathogenic bacteria that are a part of the normal gastrointestinal flora of 
animals may be pathogenic in humans.  Resistance development can be selected 
for when these animals ingest antimicrobial agents in their feed [114, 129].  
Transmission to humans can occur via consumption of meat, direct contact with 
animals, or via the environment [130-132].  Antimicrobials are also used in plant 
(sprayed aerially) and fish (added directly into the water) farming and can easily 
contaminate the water and surrounding sediment, leading to antimicrobial 
resistant bacteria in the environment [133, 134].  Antimicrobial agents in the 
environment drive antimicrobial resistance, and these resistant bacteria can serve 
as a source of resistant genes that can be spread throughout the bacteria 
population [92, 135]. 
The growing issue of antimicrobial resistance requires the judicial use of 
antimicrobials in both human medicine and in animals.  In order to preserve the 
efficacy of our antimicrobial agents in treating animals we must prevent the 
abuse of these drugs and work to minimize the risk of breeding resistant 
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microorganisms.  Using our current knowledge, some antimicrobials have been 
banned from use in food animals, and other procedures have been put in place to 
promote the appropriate use of antimicrobials in both humans and livestock 
animals. 
1.2.4 Limitations of current antimicrobial agents 
In addition to the increased emergence of resistance, there are also other 
limitations to the use of currently available antimicrobial agents including 
limited efficacy against Gram-negative bacteria, and the ineffectiveness of most 
antimicrobials against non-multiplying (stationary phase)  bacteria.  Most 
worrisome is the increase in antimicrobial drug resistance among Gram-negative 
pathogens, especially given the paucity of effective treatments under 
development that specifically target these organisms [136-138].  Gram-negative 
bacteria are particularly difficult to treat because of the unique features of these 
bacteria including the presence of a double membrane (as opposed to Gram-
positive bacteria, which only have an inner cell membrane).  This double 
membrane makes it difficult to specifically treat Gram-negative bacteria because 
many antibiotics are unable to penetrate the double membrane or are degraded 
or modified in the periplasmic space [139, 140].  Additionally, Gram-negative 
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bacteria have increased toxicity due to the incorporation of lipopolysaccharide, 
an endotoxin that can trigger a range of events important in pathogenesis 
including high fever and a drop in blood pressure [139, 140].  Studies show that 
the most predominant Gram-negative pathogens are Escherichia coli, Klebsiella 
pneumoniae, Enterobacter species, Serratia species, Pseudomonas aeruginosa, and 
Acinetobacter baumannii [141, 142]. 
In clinical infections, bacteria exist as both multiplying (logarithmic phase) 
and non-multiplying (stationary phase) bacterial cultures [48, 143].  Current 
antimicrobial agents are typically inefficient or ineffective against these non-
multiplying bacteria because most of these agents have a mechanism of action 
that requires active cell growth and replication to be effective [46, 49].  These 
non-multiplying bacteria are problematic because they can serve as a continued 
source of infection as they cycle into a reproduction phase and generate 
multiplying bacteria [143].  This can lead to chronic, recurring infections that 
require repeated administration of antimicrobial agents and prolonged treatment 
[143, 144].  Frequent and prolonged periods of antimicrobial therapy contribute 
to the emergence of bacterial resistance. 
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1.2.5 Current perspectives on antimicrobial agent development 
 Bacterial infections and antimicrobial resistance are some of the most 
significant challenges of this century and continue to increase in scope and 
impact.  The development of new antimicrobials that can serve as adequate 
treatment against these infections is a top priority.  Recently, there have been a 
few new antimicrobials brought to market and several others in clinical trial 
[145].  Most of the drugs in the pipeline are minor alterations to currently 
available antimicrobials.  Furthermore, none of these new antimicrobials are 
suitable combatants against resistance, considering that they all have limited 
activity and are only active against Gram-positive bacteria [146].  Since the 
identification of daptomycin in 1987, we have been in a “Discovery Void” with 
no new antimicrobials with a novel mechanism of action being developed [147].  
The Infectious Disease Society of America has started a “10 x 20 initiative” calling 
for the development of 10 new antimicrobial agents by the year 2020 [148].  In 
order to combat resistance development and stimulate the establishment of new 
antimicrobials, there are several mechanisms being deployed including the 
screening of natural antimicrobial compounds and development of therapies that 
stimulate the immune defense mechanisms.   
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1.2.5.1 Natural antimicrobial compounds 
Most of the existing antimicrobial agents were derived as bioactive natural 
compounds.  As stated previously, the first major antimicrobial, penicillin, was 
discovered as a metabolite of Penicillium notatum.  Screening natural compound 
libraries that contain compounds from bacteria, fungi, plants, insects and even 
higher animals can lead to the discovery of powerful antimicrobials [47, 149].  
These natural antimicrobial compounds include chemical compounds and 
substances such as antimicrobial peptides, steroids, and polyenes [150].  Today 
the scientific literature is filled with the identification of natural antimicrobial 
compounds from a variety of sources including marine organisms and insects 
[149].  Only a small fraction of the Earth’s biodiversity has been explored, and 
natural antimicrobial compounds represent a promising source of potentially 
novel antimicrobial agents.  
1.2.5.2 Immune stimulatory compounds 
Immunomodulatory therapy is a new, novel approach to combating 
bacterial infections.  Stimulation of the natural host immune system can serve as 
a critical component of improved antibacterial therapy by boosting the natural 
defense mechanisms against infection.  Many antibacterial drugs have been 
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developed to treat bacterial infections; however, antimicrobial agents are most 
effective when the infection is also being fought by healthy immune defenses.  
Immune modulators are superior to typical antibiotic therapies since they can 
potentially have broader applications (e.g., vaccine adjuvants) and reduced 
resistance emergence.  This is because in contrast to antibiotics, immune 
modulators do not directly endanger the bacteria and consequently may not 
exert selective pressure [129, 151, 152]. 
1.3 Antimicrobial Peptides 
 The increase in antimicrobial resistant organisms, coupled with a decline 
in development of new antibacterial therapies is a growing global public health 
concern.  Alternative approaches to combat these infections are needed and a 
promising approach is the use of antimicrobial peptides (AMPs).  As 
demonstrated in the previous section on the current perspectives on 
antimicrobials agents, the screening of natural compounds is an effective 
measure for the development of new antimicrobial agents. 
All forms of life are in a constant antagonistic relationship with some of 
the diverse organisms in their environment.  Both prokaryotes and eukaryotes 
have developed strategies to help protect them against these potentially harmful 
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and competitive organisms, including the evolution of a complex assortment of 
constitutive and inducible AMPs.  In humans, one of the most effective host 
defense measures against microbial attacks is the secretion of broad-spectrum 
cationic peptides by epithelial and immune cells.  Defensins, for example, are 
AMPs induced in phagocytes to destroy phagocytosed pathogens [153-155].  
Bacteria produce AMPs as a response to intra- and inter-species competition in 
the fight for niche and nutrient advantage [156-158]. 
More than 700 AMPs (e.g., defensins, cathelicidins, and magainins) have 
been discovered in humans, plants, insects, and animals [159-163].  A database of 
currently known AMPs can be found via the Antimicrobial Peptide Database 
(http://aps.unmc.edu/AP/main.php).  These peptides are an important 
component of the innate immune system found in nearly every kingdom and 
phylum [163-166].  AMPs act as a defense mechanism against invading 
microorganisms and are produced, stored, and secreted in exposed tissues, or 
synthesized de novo upon exposure to a pathogen [167, 168].  They demonstrate a 
broad-spectrum of antimicrobial activity against bacteria, fungi, protozoa, and 
viruses [166, 169-172].  These peptides are small (typically between 6-350 amino 
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acids in length), positively charged, and amphipathic (containing hydrophobic 
and hydrophilic regions) [173-176]. 
Most AMPs have a direct mechanism of antimicrobial activity via 
selectively damaging the membranes of bacteria [174, 177-179].  This membrane 
interaction allows efflux of essential ions and nutrients, leading to cell death 
through the formation of pores, membrane perturbations, or cell lysis [174-176, 
179-181].  AMPs are able to selectively target bacteria membranes due to 
fundamental differences between microbial and mammalian cells, such as the 
presence of lipopolysaccharide, and differences in transmembrane potential and 
polarization (e.g., absence of negatively charged lipids on the surface of 
eukaryotic cells and lack of strong membrane potential gradient).  Additionally, 
some AMPs may inhibit bacteria growth through intracellular targets.  Studies 
have shown that once they have translocated across the membrane these proteins 
can hinder components of cellular physiology by inhibiting DNA/RNA and 
protein synthesis, biosynthesis of the cell wall, cell division, translocation and 
protein folding [182-188].  Therefore, AMPs have a mechanism of action that may 
include several different targets, in addition to an interaction with an important 
physiological structure.   
  
33 
The broad-spectrum of activity, combined with their rapid mechanism of 
antibacterial activity, makes AMPs excellent candidates for development of 
therapeutic agents.  There are a few AMPs currently in clinical use such as 
polymyxin B (from Bacillus polymyxa) and gramicidin S (from Bacillus brevis), 
which are both naturally produced by bacteria and have been clinically used in 
topical antimicrobials for years.  Several additional AMPs currently in 
development as potential therapeutics include pexiganan for the prevention of 
diabetic foot ulcers and plectasin, which has demonstrated bactericidal activity 
against antimicrobial resistant bacteria [175, 189-191].  
Although numerous AMPs have been identified, their utility as 
therapeutics has encountered two main drawbacks.  One obstacle is proteolytic 
degradation of the peptides; however, this can be overcome with strategies such 
as chemical modifications, the use of peptidomimetic equivalents, and the 
substitution of D- or non-natural amino acids [174, 175, 192-197].  Additionally, 
AMPs are also precluded by rapid absorption (especially in the kidneys), due to 
their small size and highly charged nature [174, 189, 193, 198].  This hurdle has 
been overcome with strategies such as extension of the length (e.g., via 
attachment of polyethylene glycol) of the peptides to increase their size, direct 
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injection into the site of infection, and the use of these peptides in topical 
applications instead of systemic applications [175, 189, 199, 200].  Despite these 
shortcomings, AMPs continue to be favorable therapeutics due to the many 
advantages they have over conventional antimicrobial agents including their 
broad-spectrum of action, modest resistance induction, and their potential use 
both alone and in synergistic combination to enhance the effectiveness of other 
antimicrobials. 
1.3.1 Immunomodulatory roles of antimicrobial peptides 
As discussed previously, the innate immune response is the first line of 
defense against invading microorganisms.  The cellular and molecular systems of 
the innate immune system recognize and eliminate pathogens utilizing a variety 
of signaling pathways (e.g., toll like receptors initiated pathways) that trigger the 
rapid deployment of a wide spectrum of biological responses, which are 
relatively nonspecific.  Several studies have shown that in addition to their direct 
antimicrobial effects, some AMPs are important in triggering 
immunomodulatory responses [170, 201-207].  They include the ability to act as 
chemokines as well as to induce chemokine production, leading to recruitment of 
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leukocytes to the site of infection, promotion of wound healing, and the ability to 
modulate adaptive immune responses [201, 202, 204]. 
Certain similarities in structure between AMPs and chemokines have 
raised the possibility that AMPs have intrinsic chemotactic traits.  Indeed human 
neutrophil peptide 1 (HNP-1) and human cationic antimicrobial peptide (hCAP) 
have been reported to bind CC-chemokine receptor 6 (CCR6) on neutrophils and 
monocytes, triggering chemotaxis [206, 208-212].  Additionally, AMPs can trigger 
chemotaxis of immune cells through eliciting the secretion of chemoattractants 
from various cells.  Both HNP-1 and hCAP serve as chemotactic agents for mast 
cells and can trigger the subsequent release of histamine [206, 213, 214].  Overall, 
immune stimulatory molecules have the ability to enhance and modify the 
natural host response to infection while reducing and modulating harmful 
inflammatory effects. 
1.3.2 Antimicrobial peptides in wasp venom 
The order Hymenoptera includes Apis (e.g., bees), vespids (wasps, yellow 
jackets, and hornets), and ants.  The stinging species of this order produce venom 
that consists of a mix of enzymes (e.g., hyaluronidases, and phospholipases), 
neurotoxins, peptides, and low molecular mass substances (e.g., ions and 
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neurotransmitters) [177, 215-219].  Venom enables the insects to protect against 
predators (paralyze and/or kill), and in some species, to subdue prey [177, 190, 
215, 220].  The fast-acting mechanism of venom is evolutionarily advantageous 
since predators can cause tremendous damage to the individual insect, the 
colony, or the nest [177, 215, 219].  Venom serves a variety of purposes and the 
composition is optimized to reduce biosynthesis energy costs, while maintaining 
effectiveness both through minimized concentrations of single compounds and 
synergism between compounds [177, 215, 219, 221, 222]. 
Most adult wasps do not feed upon captured prey and instead they obtain 
their nutrients from nectar.  However, social wasps feed their brood pulpified 
prey (e.g., cockroaches and flies) and parasitic wasps lay their eggs (included as a 
component of their venom) inside or on the outside of their prey which serve as a 
microenvironment and food for the offspring [177, 215, 223-225].  Some wasp 
venom components affect the central nervous system of the prey and facilitate 
paralyzing or killing prey by allowing it to quickly reach cellular targets (e.g., 
high hyaluronidase content which increases tissue permeability and hydrolyzes 
animal connective tissue) (reviewed in [177], [215, 221]).  Additionally, the prey 
may harbor a plethora of bacteria and fungi (including human and insect 
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pathogens) that represent a hazardous environment for both the wasp and its 
offspring [223, 226-231]. 
AMPs are a component of wasp venom and serves as a defense against 
microorganisms that may infect the venom gland and reservoir, due to ingestion 
of or direct contact with infected prey during venom injection [215, 226].  Venom 
AMPs may also play a role in protecting wasp larvae against the range of 
microorganisms that they may encounter as well as  ensuring the successful 
development of their offspring [221, 226, 232, 233].  One recent study has shown 
that wasp larvae secrete a combination of AMPs to protect against microbes that 
they may encounter during growth and development inside cockroach hosts 
[223].   
1.3.3 Mastoparans 
The mastoparans are a family of peptides representing the most abundant 
group of peptides isolated from the venom of wasps [234].  These peptides 
typically share several characteristics including size (low molecular weight and 
14 amino acids in length) and structural (hydrophobic and basic amino acids that 
form an amphipathic α-helical structure) characteristics [235-238].  Table 1 lists 
several peptides that have been identified from wasps [234, 238-250].   
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Table 1: Mastoparan peptides identified from wasps. 
 
These peptides have several biological activities including  mast cell 
degranulation [234, 238, 239, 243], activation of phospholipase A2 [251, 252], and 
G protein activation [253].  Mastoparans have also demonstrated in vitro 
antimicrobial activity against both Gram-negative and Gram-positive bacteria 
[238, 241-243, 245, 254, 255]. 
The first identified peptide of the mastoparan family, Mastoparan, was 
isolated from Vespula lewisii.  It has the typical family structure in that it is a 
natural, positively charged peptide with a nonpolar center and a mostly positive, 
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polar 3’ and 5’ end [239].  Mastoparan was first identified based off its capacity to 
activate mast cells [239].  Mast cells are increasingly becoming known for their 
critical role in the innate and adaptive immune responses to infection [256-258].  
Additional studies have also shown that mastoparan has antibacterial activity 
against a few bacterial species including Staphylococcus aureus, Staphylococcus 
epidermidis, and Acinetobacter baumannii [255, 259].  The antimicrobial and 
immunomodulatory nature (via mast cell activation) of mastoparan may allow it 
to serve as a potential agent for the treatment of infections. 
1.4 Impetus for This Work 
Bacterial pathogens and the infectious diseases that they cause are a major 
global health problem.  With the continued emergence of antimicrobial resistant 
pathogens and the ability of these pathogens to easily pass along resistance genes 
to other pathogens, commonly treatable infections may become deadly due to 
increasing resistance to available treatments.  The lack of effective treatments 
against these pathogens (especially against Gram-negative bacteria) presents an 
even greater global health problem.  As mentioned in a previous section, current 
investigations into new antimicrobial agents to combat these problems focus on 
the use of natural compounds such as antimicrobial peptides and immune 
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stimulatory molecules.  In view of the previously published reports pointing to 
the intrinsic antimicrobial activity of mastoparan along with its mast cell and 
immune activating properties, we have embarked on studies examining the 
potential of mastoparan in anti-infective therapy.  The rationale described in the 
proceeding sections sets the stage for the studies outlined in Chapter 2 of this 
document.  
1.4.1 Evaluation of the antibacterial properties of mastoparan 
Previously, mastoparan was shown to demonstrate antibacterial activity 
against a few bacteria species including Staphylococcus aureus, Staphylococcus 
epidermidis, and Acinetobacter baumannii [255, 259].  In light of the need for 
development of new antimicrobials, we wanted to broaden this spectrum and 
examine the scope of antibacterial activity exhibited by mastoparan.  As 
described in an earlier section, some of the current limitations of available 
antimicrobials are their ineffectiveness against Gram-negative bacteria and non-
multiplying populations of bacteria.  Our initial observations demonstrated that 
mastoparan was effective against both Gram-negative and Gram-positive 
bacteria encouraging us to further investigate the spectrum of activity by testing 
a range of clinical isolates of bacteria including multidrug resistant strains.  
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Additionally, we tested mastoparan against both logarithmic phase (multiplying) 
and stationary phase (non-multiplying) bacteria.  Studies were also performed to 
elucidate the mechanism of action exhibited by mastoparan.  Chapter 2 of this 
document details studies that show that mastoparan has a broad spectrum of 
action and is therefore an ideal candidate for determining its future therapeutic 
potential. 
1.4.2 Evaluation of the immunostimulatory properties of mastoparan 
The ability to enhance the innate immune response is a potentially 
powerful way to prevent or treat bacterial infections.  Studies from our lab 
(unpublished data), along with others [239, 241, 260, 261], have demonstrated the 
in vitro potential of mastoparan to activate mast cells.  The notion of selectively 
activating mast cells during infection represents a marked advancement in 
scientific knowledge.  Since their discovery over 150 years ago, mast cells have 
remained an enigma.  Although they are well known to be powerful mobilizers 
of immune cells, their physiological function has largely been overlooked.  This 
is partly attributable to their well-known contribution to the pathology of a 
number of common inflammatory disorders such as asthma, rheumatoid 
arthritis, and multiple sclerosis. 
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Several years ago, members of the Abraham laboratory reported that mast 
cells played a key role in immune surveillance by functioning as powerful 
recruiters of neutrophils and dendritic cells to sites of infection [262].  There is 
also a growing body of evidence pointing to mast cells as critical mediators of 
tissue remodeling and wound repair [258, 263].  These observations suggest that 
mast cells play a multi-faceted role in combating infections and that purposeful 
activation of mast cells at infected sites might be beneficial.  The findings that 
mast cell activating molecules can be administered locally to boost innate and 
adaptive immune responses, without any accompanying toxicity [264] is 
supportive of this notion and has significant translational implications.  
Given our initial in vitro observations of the ability of mastoparan to 
induce mast cell degranulation, we were led to further investigate the in vivo 
capacity of mastoparan to activate mast cells and stimulate neutrophil 
recruitment.  This work involved the continuation of studies completed by a 
previous member of the Abraham laboratory, Dr. Joseph Onyiah, and includes a 
series of studies described in Chapter 2 that elucidate the potential of 
mastoparan to cause mast cell activation and neutrophil influx in the peritoneal 
cavity.  In order to determine the amount of neutrophil influx encountered in 
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mice, additional studies were also performed, utilizing a bacterial skin infection 
model that included the use of both wild type and mast cell deficient mice.  We 
incorporated the latter into our model to distinguish the contribution of mast cell 
activation.  This work demonstrates the in vivo ability of mastoparan to stimulate 
the immune system and points to the important role mast cells play contributing 
to the immunomodulatory capabilities of mastoparan. 
1.4.3 Evaluation of the therapeutic potential of mastoparan 
Mastoparan was preferentially chosen as a prospective therapeutic for this 
study, based on several distinctive features.  This peptide is potentially superior 
to other previously described AMPs that only exhibit antibacterial activity 
because it possesses potent immunomodulatory properties in addition to its 
antibacterial activity.  This combination may therefore make mastoparan 
markedly more effective in vivo.  Although AMPs were identified over a decade 
ago, they were not considered as therapeutic agents until recently, when 
pressure increased to develop novel approaches to combat resistant pathogens.  
Previous sections have outlined the therapeutic limitations in the 
treatment of skin infections.  Given that mast cells reside largely at skin surfaces, 
where Gram-positive Staphylococcus and Streptococcus species are the primary 
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pathogens, we sought to investigate whether the activation of mast cells during 
infection may stimulate the innate immune system leading to better clearance of 
these bacteria.  We suspected that the direct bactericidal activity, combined with 
the ability to activate mast cells and mobilize innate immune response, would 
result in mastoparan being a more effective therapeutic (Figure 1).  This work is 
described in detail in Chapter 2 and highlights the potential utility of mastoparan 
as a therapeutic against bacterial skin infections. 
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Figure 1: Potential antibacterial and immunomodulatory role of mastoparan.  
The ability of mastoparan to exhibit both antimicrobial and immune stimulatory 
activity may enhance its ability to cause bacterial clearance.    
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Chapter 2: Dual Action Immunomodulatory and Broad-
Spectrum Antibacterial Activity of Wasp Venom Peptide 
2.1 Introduction 
The skin, which harbors a distinct and diverse microbiome, is a major site 
of microbial attack and infection.  Bacterial skin infections are initiated when a 
break in the skin (e.g., from a cut, insect bite or post-operative wound) occurs, 
allowing one or more of the skin’s colonizing bacteria to overcome the host 
immune responses leading to an infection of the skin or soft tissue.  Bacteria are 
responsible for a variety of skin conditions such as abscesses, ulcers, impetigo 
and cellulitis [33, 35, 90, 265].  Bacterial skin infections have emerged as a 
significant public health problem.  In the United States, skin and soft tissue 
infections are among the top conditions which require use of antimicrobial 
therapy and they account for 7% to 10% of all hospitalizations [33, 266, 267].  
These high rates of incidences are because infections of the skin are notoriously 
difficult to eradicate with conventional antimicrobial agents for multiple reasons.  
First, there is the coexistence of multiplying and non-multiplying bacteria that 
exist in most infections [48, 143, 268].  Whereas the actively growing bacteria are 
cleared, their static or non-multiplying counterparts are usually unaffected by 
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current antimicrobial treatments [46-49, 269, 270].  Second, many antimicrobial 
treatments are ineffective against the growing emergence of multidrug resistant 
bacteria [43, 271-277].  Third, many antimicrobial agents are typically effective 
against only Gram-positive or Gram-negative bacteria and therefore lack broad-
spectrum activity needed to be effective against different types of infecting 
bacteria.  The ineffectiveness of existing therapeutics combined with the increase 
in the number of bacterial infections, represent a significant health threat and 
therefore we are in dire need of new antimicrobial agents to treat these 
infections. 
Antimicrobial peptides (AMPs) are natural, evolutionarily conserved 
oligopeptides that contribute to innate immunity of the host and are found 
among all classes of life.  These natural peptides, ranging from 6 – 350 amino 
acids in length [172, 174, 175, 278], typically work by inducing structural 
perturbations and increasing permeability of the microbial membrane 
phospholipid bilayer [176, 178, 279].  AMPs have been isolated from a wide 
range of animals and anatomical sites including venom sacs of wasps, bees, and 
scorpions, the skin of frogs, and epithelial mucosa and vascular compartment of 
humans and other mammals.  These peptides have potent antimicrobial activity 
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against a wide range of microorganisms and are increasingly being viewed as 
potential therapeutic agents and viable alternatives for conventional 
antimicrobials [165, 166, 168, 170].  However, in spite of their in vitro 
effectiveness, their in vivo effectiveness has been surprisingly disappointing.  The 
limited in vivo effectiveness of AMPs is attributable, at least in part, to their short 
half-life, as AMPs are susceptible to early degradation by host proteases.  
Additionally, these peptides are often positively charged, allowing them to be 
readily adsorbed by host cells whose surfaces are negatively charged [174, 175, 
190, 280, 281].  
Mastoparans are a family of peptides that are the most abundant AMPs in 
wasp venom [232, 234, 282].  AMPs in this family typically vary in sequence by 
one or two residues.  The first mastoparan identified from this family of 
peptides, mastoparan (Vespula lewisii), is composed of 14 amino acid residues 
(INLKALAALAKKIL-NH2), a nonpolar center, and mostly positive polar 3’ and 
5’ ends [239].  Mastoparans are discharged from venom sacs when wasps lay 
their eggs inside or on cockroaches and flies.  These AMPs presumably protect 
the emerging larvae from microbes at the necrotic sites surrounding the laid eggs 
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and functions to protect the venom gland and reservoir from invading 
microorganisms [215, 221, 226, 232, 233]. 
Interestingly, the mastoparans also reportedly possess a wide range of 
biological activity in eukaryotic cells including stimulation of some 
phospholipases [251, 252], and G proteins within various cells [253, 283-285].  
These peptides are also known for their extensive degranulation of mast cells in 
higher animals [233, 236-239, 243, 251].  Since there is growing evidence that mast 
cells orchestrate the early innate and adaptive immune responses to infection, we 
hypothesized that in addition to their antimicrobial actions, mastoparans may 
possess additional traits for boosting host immunity.  We reasoned that these 
dual capabilities of mastoparan might make it an especially potent agent for 
treating infections, such as skin infections, that are refractive to conventional 
antibiotics.  Additionally, in spite of the literature [243, 254, 255, 286] describing 
the antibacterial actions of mastoparan, relatively few studies have undertaken 
an in depth examination of its scope, mechanism of action and therapeutic 
potential.  Therefore, here we have examined the range and spectrum of 
antibacterial action of mastoparan and then evaluated its in vivo effectiveness 
against skin infections utilizing standard murine models. 
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2.2 Materials and Methods 
2.2.1 Bacteria strains and growth conditions 
All bacteria strains used in this investigation were clinical isolates selected 
for this study by the Duke University Clinical Microbiology Lab (Durham, NC).  
From frozen stock, bacteria were grown overnight via agar plating.  Bacteria 
from two to three normal-appearing colonies were selected to prepare liquid 
cultures.  Overnight liquid cultures were inoculated in either Luria Broth (LB; 
Becton, Dickinson and Company, Franklin Lakes, NJ) or Brain Heart Infusion 
(BHI; Becton, Dickinson and Company, Franklin Lakes, NJ) at 37°C, and these 
cultures were aerated at 250 rpm. 
2.2.2 Antimicrobial agents 
Synthetic mastoparan (Vespula lewisii, INLKALAALAKKIL-NH2) was 
obtained commercially at >90% purity from BACHEM California, Inc. (Torrance, 
CA) or CPC Scientific (Sunnyvale, CA).  The antibiotics: tobramycin, polymyxin 
B sulfate, neomycin, gramicidin and bacitracin; were all obtained from Sigma-
Aldrich (St. Louis, MO).  Neosporin® (Johnson & Johnson Consumer Companies, 
Inc.), which contains the active ingredients polymyxin, 5,000 units/g; bacitracin, 
400 units/g; and neomycin, 3.5 mg/g, was purchased as an over-the-counter drug. 
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2.2.3 Mice 
Female six to eight weeks old C57BL/6 mice obtained from the National 
Cancer Institute Animal Production Program (Frederick, MD) and mast cell 
deficient Wsh/Wsh (bred in the Duke University animal facility) were used for all 
mouse experiments in this study.  Mice were bred and housed in community 
cages at the Animal Care Facilities at Duke University.  All mouse experiments 
were done according to protocols approved by the Duke Division of Laboratory 
Animal Resources and the Duke University Institutional Animal Care and Use 
Committee.  
2.2.4 Broth microdilution bacteria susceptibility test 
The minimum inhibitory concentration (MIC) was assayed by the broth 
microdilution method according to procedures outlined by the National 
Committee for Clinical Laboratory Standards [287].  The initial inoculum was 
adjusted to 5 x 105 colony-forming units per milliliter.  In order to monitor the 
validity and reproducibility of the assay, incubations with bacteria were carried 
out in parallel with decreasing concentrations of antibacterial agent.  The 
concentration range assayed was 0.97 µg/mL – 2 mg/mL.  A twofold serial 
dilution of each antimicrobial agent was prepared in the appropriate medium 
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(LB or BHI).  To each well of a sterile polypropylene 96-well microtiter cell-
culture plate (Sigma-Aldrich), 40 μL portions of each peptide dilution were 
added along with 40 μL of each bacterium.  The microtiter plates were incubated 
at 37°C overnight, and each concentration was run in duplicate.  Growth controls 
without antibacterial peptide were included in each test.  The MIC was taken as 
the lowest concentration of antibacterial agent that completely inhibits visible 
bacteria growth.  Values were obtained from 3-4 independent experiments.   
2.2.5 Time-kill kinetic assay 
A time-kill kinetic assay was used to measure bacteria viability or growth 
as a factor of time.  This assay was performed following the National Committee 
for Clinical Laboratory Standards guidelines [288].  Cultures of Pseudomonas 
aeruginosa, Escherichia coli, and Staphylococcus aureus were incubated overnight at 
37°C and then diluted 1/20,000.  The bacteria were then plated into a 96-well 
microtiter plate and optical density (OD) readings (630nm) were taken every 15 
minutes using a BioTek® absorbance microplate reader.  Once the bacteria 
reached either log or stationary phase, mastoparan was added to the bacteria 
culture.  In a parallel experiment, 10 µL of mixtures were serially diluted in 
media to minimize the carryover effect and then plated onto LB plates and 
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incubated overnight to obtain viable colony counts.  Growth controls without 
any antibacterial agent added were performed in parallel.  Data presented as the 
average of 2-3 independent experiments.   
2.2.6 Fluorescence microscopy assay to measure cell membrane 
permeability 
Cell membrane permeability was measured using the LIVE/DEAD® 
Bacterial Viability Kit (BacLight™).  Pseudomonas aeruginosa was grown overnight 
at 37°C and then incubated for 4 hours in the presence of mastoparan (31 
µg/mL), polymyxin (4 µg/mL), or tobramycin (1 µg/mL).  These concentrations 
represent twice the demonstrated MIC (Table 3) for each respective 
antimicrobial.  In addition, a control experiment was performed whereby 
bacteria were incubated without any antibacterial agent present.  Equal volumes 
of the kits two dye components, SYTO 9 and propidium iodide, were mixed 
together, and added to the bacteria suspension (1.5 μL of dye mixture per 500 μL 
of bacteria suspension).  The suspension was then incubated at room 
temperature in the dark for 15 minutes.  After incubation, the bacterial 
suspension was fixed between a slide and coverslip using Prolong Gold antifade 
reagent (Molecular Probes) and viewed via fluorescence microscopy.  The SYTO 
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9 dye is membrane permeable and labels all bacteria and propidium iodide is 
membrane impermeable and only labels bacteria cells with damaged 
membranes, as it is unable to penetrate healthy bacterial cells.  Bacteria with 
intact cell membranes stain fluorescent green and those with damaged 
membranes stain fluorescent red. 
2.2.7 Election microscopy 
Pseudomonas aeruginosa was cultured overnight at 37°C and then adjusted 
for log phase of growth.  Bacteria (5 x 105 cfu/mL) were then incubated for 3 
hours in the presence of mastoparan.  Mastoparan was used at a concentration of 
15.6 µg/mL, which is its demonstrated MIC, and 31 µg/mL, a two-fold serial 
dilution above its MIC.  Bacterial cultures were harvested, washed, and fixed 
with a fixation solution.  Sample processing, sectioning, and examination by 
transmission electron microscope were performed by the Laboratory for 
Advanced Electron and Light Optical Methods at the College of Veterinary 
Medicine, North Carolina State University (Raleigh, NC).    
2.2.8 Lactate dehydrogenase (LDH) cytotoxicity assay 
 Cytotoxicity was assessed using a LDH cytotoxicity kit (Sigma-Aldrich) 
according to manufactures instructions.  Briefly, HeLa cells were seeded in a 96-
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well tissue culture plate at a density of 1 x 104 cells per well and incubated 
overnight.  After overnight incubation various dilutions of mastoparan (ranging 
between 0.49 µg/mL – 2 mg/mL) were added to the cells along with fresh media.  
Cell death was evaluated by the amount of LDH released into the culture 
medium after 4 hours of mastoparan treatment.  The cell culture media from 
treated cells was transferred to a new microplate and mixed with the kit 
reagents.  The change in absorbance of the samples was measured at 450 nm with 
an absorbance plate reader to determine LDH release.  The amount of LDH 
released by cells killed with Triton X-100 was considered as total LDH release or 
maximal cell death.  
2.2.9 β-Hexosaminidase assay for in vitro mast cell degranulation 
As described previously by McLachlan et. al. [289], femurs from C57BL/6 
mice were recovered from bone marrow, which was then cultured in complete 
RPMI 1640 medium containing 10% fetal bovine serum (FBS), 1% HEPES, amino 
acids, penicillin, streptomycin, and 10% recombinant stem cell factor 
supplemented with 2 ng/ml IL-3 for 4 weeks to obtain bone marrow mast cells 
(BMMCs).  BMMCs were incubated for 1 hour at 37°C in the presence of various 
concentrations of mastoparan (ranging between 5 µM – 80 µM, 7.5 µg/mL – 120 
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µg/mL).  The mast cells were centrifuged, the supernatant was then removed and 
mixed with the substrate p-nitrophenyl-N-acetyl-β-D-glucosaminide to test for 
the release of β-hexosaminidase by measuring the change in absorbance at 405 
nm on an absorbance plate reader.  Percent degranulation above baseline was 
calculated based on β-hexosaminidase release after corrections for spontaneous 
release from unstimulated cells was taken into consideration.   
2.2.10 Mastoparan treatment of mice intraperitoneally  
 Mastoparan, at various concentrations, was injected into the peritoneal 
cavity of 6 to 8 weeks old C57BL/6 mice using a 1 mL syringe and a 30.5-gauge 
needle.  At the specified time points, mice were sacrificed and a peritoneal lavage 
was performed with 3 mL of phosphate buffered saline (PBS).  After 20 seconds 
of shaking, the peritoneal contents were recovered using a sterile pipette. 
2.2.10.1 Microscopic analysis of peritoneal lavage 
 Following recovery of the lavage samples, a cytospin (Cytospin 3, Sandon 
Inc., PA) was used to fix the samples on slides.  Samples were stained with 5% 
toluidine blue and viewed under a microscope to evaluate the percentage of mast 
cell degranulation.  Mast cells were scored as fully granulated or having partial 
or complete granule loss.  The number of degranulated versus the number of 
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non-degranulated mast cells were counted and the percentage degranulation 
reported. 
2.2.10.2 Microscopic analysis of mesenteric mast cells 
Specimens of mouse mesentery were prepared by dissection of the 
intestine and mesentery between the colon and root of mesentery from the 
peritoneal cavity of the mice treated with mastoparan or PBS as a control in a 
manner similar to previously described procedures [290, 291].  Briefly, samples 
were acetone-fixed, carefully spread on a microscope slide and slightly flattened.  
After the intestine was removed, samples were incubated in the presence avidin 
FITC (Molecular Probes) to allow for immunohistochemical study.  Samples 
were then washed three times (10 min each) in PBS.  Each sample was covered 
with ProLong antifade reagent (Molecular Probes) and a coverslip.  Confocal 
images of stained tissue sections were obtained with a three-laser Nikon 
Confocal Laser Scanning Instrument (Nikon USA).  Images were obtained under 
oil immersion with a Plan Fluor 20.0/0.75/.35 multiobjective and EZ-C1 Nikon 
software (Silver Version 2.01). 
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2.2.10.3 Myeloperoxidase assay for neutrophils 
Neutrophil influx into the peritoneum was evaluated by measuring the 
amount of myeloperoxidase (MPO) present in the peritoneum following 
previously described methods [292].  Neutrophils have an abundance of the 
MPO enzyme and it has been shown to be a useful and reliable maker for 
neutrophil influx in inflammatory diseases [292, 293].  Briefly, 1mL of peritoneal 
lavage samples were centrifuged at 12,000 rpm for 10 minutes and the pellet was 
resuspended in 1 mL of potassium phosphate buffer (50 mM, pH 6.5) with 0.5% 
hexadecyltrimethylammonium bromide (HTAB) to release the MPO from the 
neutrophils.  The samples were frozen and thawed twice and then centrifuged at 
12,000 rpm for 2 minutes.  Then 20 uL of the supernatants were analyzed in 
triplicate by transferring to a 96-well plate and adding 200 uL of 50 mM 
potassium phosphate buffer (pH 6.0) with 0.167 mg/mL o-dianisidine 
dihydrochloride and 0.0005% H2O2.  The colorimetry of the supernatants was 
measured using an absorbance plate reader to measure optical density at 460 nm.  
MPO content was calculated using a standard curve, which was established 
using purified MPO.  
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2.2.11 Superficial skin colonization and infection models 
The skin colonization and infection models were performed as described 
previously [143, 294] using C57BL/6 mice.  Mice were anesthetized by 
intraperitoneal injection with 100 μL of a 1:3:15 mixture of 20 mg/ml xylazine, 
100 mg/ml ketamine hydrocholoride, and sterile PBS.  The backs of the mice were 
shaved (electric clipper) and hair removed by chemical depilation (Nair; Church 
& Dwight CO.).  For the skin colonization model, log phase or stationary phase 
Staphylococcus aureus cultures were added to a 2 cm2 area or the shaved skin, 
marked with a surgical skin marker (Covidien), and allowed to dry for 20 
minutes.  After drying, treatment with mastoparan or neosporin was performed 
by spreading the antibacterial agent on the 2 cm2 area of skin with the aid of a 
pipette and utilizing the pipette tip to spread the antimicrobials to the entire 
infected area.  Mastoparan was infused in a vehicle of olive oil (to enable the 
drug to stay in place on the skin) and DMSO (to encourage transdermal 
migration) to allow for transdermal passage.  
For the skin infection model, C57B/6 mice or mast cell deficient mice 
(Wsh/Wsh) were injected (using a 25-gauge needle) intradermally with 100 μl of 
mid-logarithmic growth phase (A600= 0.6, ~5 x 108 CFU) of Staphylococcus aureus 
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complexed to Cytodex (Sigma-Aldrich) beads as a carrier.  Beginning at 12 hours 
after infection, mice were treated with either mastoparan or Neosporin every 12 
hours.  Lesion sizes were accessed daily by measuring the vertical and 
perpendicular diameters and calculating the area using the formula for an 
ellipse: (vertical diameter/2) × (perpendicular diameter/2) × π.  At various time 
points, skin from the infection site was harvested using an 8mm biopsy punch, 
homogenized and plated for enumeration of colony-forming units.   
To determine skin myeloperoxidase (MPO) levels, skin biopsies were 
homogenized an 1 mL of potassium phosphate buffer (50 mM, pH 6.5) with 0.5% 
hexadecyltrimethylammonium bromide (HTAB) to release the MPO from the 
neutrophils.  The samples were frozen and thawed twice and then centrifuged at 
12,000 rpm for 2 minutes.  Then 20 uL of the supernatants were analyzed in 
triplicate by transferring to a 96-well plate and adding 200 uL of 50 mM 
potassium phosphate buffer (pH 6.0) with 0.167 mg/mL o-dianisidine 
dihydrochloride and 0.0005% H2O2.  The colorimetry of the supernatants was 
measured using an absorbance plate reader to measure optical density at 460 nm.  
MPO content was calculated as units per gram using a standard curve, which 
was established using purified MPO.    
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2.2.12 Dermal toxicity study 
 The dermal toxicity of mastoparan was investigated using C57B/6 mice.  
Mice were anesthetized by intraperitoneal injection with 100 μL of a 1:3:15 
mixture of 20 mg/ml xylazine, 100 mg/ml ketamine hydrocholoride, and sterile 
PBS.  The backs of the mice were shaved (electric clipper) and hair removed by 
chemical depilation (Nair; Church & Dwight CO.).  Mastoparan (50 µg or 100 µg) 
was administered every 12 hours via topical application or intradermal injection 
for 14 days.   
Topical application of mastoparan was accomplished by applying 10 µL of 
mastoparan infused in olive oil and DMSO (to enable the drug to stay in place 
and facilitate transdermal migration) directly to a 2 cm2 area of the shaved skin, 
marked with a surgical skin marker (Covidien).  Mastoparan was applied to the 
skin with a pipette, using the pipette tip to facilitate spreading.  Intradermal 
injection of mastoparan was achieved using a 25-gauge needle to inject 100 µL of 
mastoparan directly under the upper epidermal layer of the backs of shaved 
mice.  Before and after each treatment, clinical signs of related adverse reaction 
were monitored including temperature, body weight, observable inflammation, 
and observable changes in behavior.  
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2.3 Results 
2.3.1 Mastoparan exhibits broad-spectrum antibacterial activity 
against Gram-negative and Gram-positive bacteria 
In order to explore the range of antibacterial efficacy demonstrated by 
mastoparan, we first screened randomly selected clinical isolates of Gram-
positive (n=4) and Gram-negative (n=11) bacteria for mastoparan sensitivity 
using a broth microdilution method (Table 2).  
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Table 2: Mastoparan exhibits broad-spectrum antibacterial activity against 
Gram-positive and Gram-negative bacteria.  Microbes (5 x 105 CFU per mL) 
were incubated overnight in the presence of decreasing serial dilutions of 
mastoparan and the minimum inhibitory concentration (MIC) was recorded as 
the lowest concentration needed to visibly inhibit 100% of bacterial growth.  This 
data demonstrates that mastoparan has a broad-spectrum of antibacterial 
activity. 
 
These clinical isolates were incubated in the presence of decreasing serial 
dilutions of mastoparan to determine the minimum amount of peptide required 
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to inhibit bacteria growth.  The MIC of mastoparan against Gram-positive 
bacteria ranged between 1.9 – 125 μg/mL (1.3 – 84.5 μM).  Against Gram-negative 
bacteria, the MIC ranged between 15.6 – 125 μg/mL (10.6 – 84.5 μM).  This data 
indicates that mastoparan is active against clinical isolates of both Gram-negative 
and Gram-positive bacteria.  The data presented here also demonstrates that 
there is no distinct difference in bacteria susceptibility between Gram-negative 
and Gram-positive bacteria since mastoparan demonstrated a similar range of 
efficacy against both types of bacteria.  Our studies reveal that mastoparan 
demonstrates a broad-spectrum of antibacterial activity, and is therefore a 
favorable antibiotic candidate since most commonly marketed antibiotics have 
limited activity against only Gram-negative or Gram-positive bacteria. 
2.3.2 Mastoparan has a broader range of activity against bacteria in 
comparison to selected marketed antibiotics 
Many new antimicrobial agents do not make it to market due to the 
inability to demonstrate superiority of the new drug to current therapies.  After 
determining that mastoparan is an effective broad-spectrum antibacterial, we 
sought to investigate the efficacy of mastoparan in comparison to six marketed 
antimicrobial agents in order to elucidate its potential as a superior anti-infective 
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therapeutic.  We performed a broth microdilution test with mastoparan, 
tobramycin, neomycin, polymyxin, gramicidin, and bacitracin against Escherichia 
coli, Pseudomonas aeruginosa, and Staphylococcus aureus (Table 3).   
Table 3: Mastoparan is more active against bacteria (both Gram-negative and 
Gram-positive) than selected marketed antibiotics.  Microbes were incubated 
overnight in the presence of decreasing serial dilutions of the noted antimicrobial 
agents and the minimum inhibitory concentration (MIC) was recorded as the 
lowest concentration needed to inhibit bacteria growth.  This data strongly 
suggests that mastoparan has a broader range of antibacterial activity in 
comparison to the other antimicrobial agents tested. 
 
Tobramycin and neomycin are both aminoglycosides, particularly 
effective against Gram-negative bacterial species by binding to the bacterial 
ribosomal subunit.  They were selected for comparison due to their known 
efficacy against Gram-negative bacteria and their classification as an 
aminoglycoside.  Additionally, neomycin was selected due to its inclusion as an 
active ingredient in Neosporin (Johnson & Johnson Consumer Companies, Inc), a 
commonly used topical antimicrobial agent.  Polymyxin is a cyclic peptide 
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effective against Gram-negative bacteria through a cell membrane interaction via 
the lipid A component of the lipopolysaccharide [295].  It was selected for 
comparison due to its mechanism of action, peptide structure, and it is also an 
active ingredient in Neosporin.  Both gramicidin and bacitracin are AMPs 
effective against Gram-positive bacteria via a direct interaction with cell 
membrane phospholipids [296-298].  They were selected for comparison to 
mastoparan due to their similar peptide nature and mechanism of action.  
Additionally, bacitracin was selected due to its inclusion as an active ingredient 
in Neosporin.   
Tobramycin and polymyxin were only effective when tested against the 
Gram-negative bacteria.  Neomycin demonstrated antibacterial activity against 
both Gram-negative and Gram-positive bacteria.  However, it is active against 
S.aureus at a much higher concentration when compared to its demonstrated 
MIC against E. coli, and P. aeruginosa.  Gramicidin did not demonstrate any 
activity at the concentrations (between 0.5 µg/mL – 2 mg/mL) we tested and 
bacitracin demonstrated activity against all three bacteria strains but at 
concentrations (500 µg/mL – 1 mg/mL) much higher than that demonstrated by 
mastoparan (7.8 µg/mL – 15.6 µg/mL).  Mastoparan demonstrates activity against 
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both Gram-negative and Gram-positive bacteria with a similar MIC for both 
types of bacteria.  Therefore, it appears that mastoparan has superior efficacy, 
when compared to gramicidin and bacitracin, and a broader spectrum of action 
in comparison to tobramycin, neomycin, and polymyxin. 
2.3.3 Mastoparan exhibits antibacterial activity against resistant 
clinical isolates 
Due to the growing trend in antimicrobial resistance and having observed 
the efficacy of mastoparan against standard clinical isolates, we sought to 
investigate if mastoparan is effective against resistant strains of bacteria.  
Researchers have identified some particularly problematic pathogens that 
include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, 
Acinetobacter baumanni, Pseudomonas aeruginosa, and Enterobacter species 
(“ESKAPE pathogens”) [138, 299, 300].  These pathogens cause the majority of 
nosocomial infections and are able to “escape” the actions of antibacterial agents 
as their resistance prevalence, transmission, and pathogenesis increases.  In order 
to examine the ability of mastoparan to serve as a potential antibacterial against 
these pathogens, we tested the peptide against methicillin-resistant 
Staphylococcus aureus, extended spectrum beta-lactamase Klebsiella pneumonia and 
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Escherichia coli, and resistant Pseudomonas aeruginosa via the broth microdilution 
method.  The data presented in Table 4 shows that mastoparan demonstrated 
antibacterial activity against all the resistant strains tested (MIC = 7.8 – 125 
μg/mL) in a range similar to the MIC (Table 2) demonstrated against the 
standard clinical isolates tested in this study.  This data suggests that mastoparan 
can serve as a powerful antibacterial agent against some resistant organisms and 
may therefore serve as a solution to the current rise in multidrug resistance.   
Table 4: Mastoparan exhibits antibacterial activity against multidrug resistant 
bacteria.  Multidrug resistant clinical isolates of E. coli, P. aeruginosa, K. 
pneumonia, and S. aureus were incubated overnight in the presence of decreasing 
serial dilutions of mastoparan.  The MIC was recorded as the lowest 
concentration needed to visibly inhibit 100% of bacterial growth.  These results 
show that these multidrug resistant strains are susceptible to mastoparan. 
 
2.3.4 Mastoparan disrupts bacterial membrane integrity 
In light of studies demonstrating that most antimicrobial peptides similar 
in size and structure to mastoparan utilize a mechanism of action involving an 
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interaction with the cell membrane, we investigated whether mastoparan has an 
effect on cell membrane permeability.  To test if the mechanism of action utilized 
by mastoparan involves an increase in membrane permeability, P. aeruginosa was 
incubated in the presence of mastoparan, polymyxin, or tobramycin at 
concentrations two-fold higher than their respective MICs.  Polymyxin 
demonstrates antibacterial activity against Gram-negative bacteria through a cell 
membrane interaction whereby it binds to lipopolysaccharide and alters bacterial 
outer membrane permeability [77, 295], thus it is used in this assay as a positive 
control.  Tobramycin was selected for comparison due to its efficacy against 
Gram-negative bacteria and because it is an aminoglycoside whose mechanism 
of action involves it binding to the bacterial ribosomal subunit therefore 
inhibiting the synthesis of proteins vital for bacterial growth [301].   
We used a LIVE/DEAD® Bacterial Viability Kit (BacLight™) to determine 
if mastoparan disrupts bacterial membrane integrity.  The kit contains two dyes, 
SYTO 9, a membrane permeable dye that labels all bacteria and propidium 
iodide, a membrane impermeable dye, which only labels bacteria cells with 
damaged membranes.  Bacteria with intact cell membranes stain fluorescent 
green and those with damaged membranes stain fluorescent red.  The data 
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presented in Figure 2 shows that bacteria incubated in the presence of both 
mastoparan and polymyxin have green and red fluorescent staining, indicating 
that their membrane integrity has been disrupted.  Bacteria incubated with 
tobramycin, as well as the control bacteria that were not incubated in the 
presence of any antibacterial, only fluorescence green indicating that their cell 
membranes are intact.   
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Figure 2: Mastoparan disrupts bacterial membrane integrity as demonstrated 
by fluorescence microscopy.  P. aeruginosa was incubated for four hours in the 
presence of mastoparan (31 µg/mL), polymyxin (4 µg/mL), or tobramycin (1 
µg/mL) and then stained using a LIVE/DEAD® Bacterial Viability Kit 
(BacLight™).  After staining, the bacteria were mounted on a slide using Prolong 
Gold antifade reagent (Molecular Probes) and viewed via fluorescence 
microscopy.  This data shows that mastoparan affects the membrane integrity of 
bacterial cells. 
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We also examined the ultra-structure of P. aeruginosa by transmission 
electron microscopy after treatment with mastoparan (Figure 3).  At its minimum 
inhibitory concentration (15.6 µg/mL), mastoparan caused cell membrane 
disruption exhibited by extensive membrane blebbing, ruffling and detachment 
(Figure 3C & D).  Furthermore, reduced electron density was demonstrated in 
bacteria cultures treated with mastoparan (Figure 3C-F) in comparison to the 
control (Figure 3A-B) signify a loss in cytoplasmic contents.  At a two-fold higher 
concentration (31 µg/mL), we noticed that treatment with mastoparan led to 
ruptured membrane and expelled cellular contents (Figure 3E & F).  
Cumulatively, these data strongly suggests that mastoparan causes extensive 
membrane permeability and utilizes a cell membrane interaction as its 
mechanism of bactericidal action in a concentration dependent manner. 
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Figure 3: Mastoparan disrupts bacterial membrane integrity as demonstrated 
by transmission electron microscopy.  P. aeruginosa after incubation in the 
presence of mastoparan via transmission electron microscopy. (3A) Control P. 
aeruginosa, no antibacterial added. (3B) Control bacteria at a higher magnification 
demonstrating electron dense bacteria with a continuous membrane.  
Mastoparan at 15.6 µg/mL (3C, higher magnification 3D), and mastoparan at 31 
µg/mL (3E, higher magnification 3F) shows bacteria incubated in the presence of 
mastoparan demonstrated: 1: membrane blebbing, 2: membrane ruffling, 3: 
membrane detachment, 4: loss of electron density, 5: ruptured membrane, 6: 
release of cytoplasm.  Left panels size bars represents 0.5 µm.  Right panels size 
bars represent 200 nm.  This data shows that mastoparan affects the membrane 
integrity of bacterial cells and causes loss of cellular contents. 
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2.3.5 Mastoparan does not elicit cytotoxicity at the concentrations 
necessary for its antibacterial activity 
 Many AMPs that were previously studied with a goal to exploit their 
antimicrobial activity have been restricted from clinical use due to their toxicity 
profiles.  AMPs’ proclivity for a mechanism of action that involves membrane 
interaction increases the likelihood of cytotoxicity.  However, AMPs can 
selectively target bacterial membranes based on differences between human cells 
and bacteria cells including the presence of cholesterol, and differences in 
membrane potential.  Having observed the potent activity of mastoparan on 
bacterial membrane permeability, we sought to determine the potential 
cytotoxicity of mastoparan in relation to human cells.   
We tested the cytotoxicity of mastoparan by measuring the amount of 
lactate dehydrogenase (LDH) released from HeLa cells incubated in the presence 
of various concentrations (ranging between 0.49 µg/mL – 2 mg/mL) of 
mastoparan.  LDH is released by cells with damaged membranes and has been 
used to evaluate toxicity of cells [302].  The data presented in Figure 4 shows that 
mastoparan does not demonstrate cytotoxicity at concentrations between 0.49 
µg/mL – 250 µg/mL.  At these concentrations, the minimal amount of LDH 
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activity seen is similar to that of the controls (cells alone and media alone).  These 
concentrations are within the range necessary for mastoparan’s antibacterial 
activity, which is between 1.9 µg/mL – 125 µg/mL.  At high concentrations above 
500 µg/mL, mastoparan does exhibit some cytotoxicity.  This data suggests that 
mastoparan does not exhibit cytotoxicity against human cells at the concentration 
required for the killing of bacteria. 
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Figure 4: Mastoparan does not exhibit cytotoxicity to HeLa cells at 
concentrations similar to those needed for its antibacterial activity.  HeLa cells 
were incubated in the presence of mastoparan at the noted concentrations.  A 
LDH activity assay was performed to determine the amount of LDH released 
from these cells.  This data shows that at concentrations between 0.49 µg/mL – 
250 µg/mL, there was no release of LDH in comparison to the cells and media 
alone controls.   
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2.3.6 Mastoparan exhibits a kinetically rapid mechanism of bacteria 
growth inhibition 
During infection, bacteria exist in both log and stationary phase.  Thus, 
ideal antimicrobial agents will exhibit activity against bacteria in both log and 
stationary phase.  We investigated the antibacterial activity of mastoparan 
against log phase P. aeruginosa cultures in which bacteria were undergoing 
replication.  We also tested mastoparan against stationary phase P. aeruginosa, 
which have minimal replication, and growth.  Mastoparan was added to bacteria 
cultures in each of these two growth phases and we assessed the impact of 
mastoparan using optical density (OD) and agar plating to determine viability 
counts. 
Figure 5A & B reveals that addition of mastoparan prevented the increase 
in OD of log phase bacteria and markedly reduced colony viability count within 
half an hour after addition of mastoparan.   
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Figure 5: Mastoparan is effective against log phase bacteria.  P. aeruginosa was 
incubated in the presence of mastoparan at the noted concentration.  (A) Optical 
density and (B) colony-forming unit measurement of bacterial growth inhibition 
using a log phase culture of P. aeruginosa.  Red line demonstrates when 
antibacterial was added.  This data shows that mastoparan rapidly kills log 
phase bacteria.  The same experiment was performed using E. coli and S. aureus 
with similar results (data not shown). 
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Interestingly, addition of mastoparan to stationary phase bacteria did not affect 
OD; however, the culture exhibited a drastic and significant reduction in colony 
viability count (Figure 6A&B).  These findings are consistent with the idea that 
mastoparan is able to rapidly kill both log and stationary phase bacteria.  Similar 
results were observed when mastoparan was added to E. coli and S. aureus 
cultures in log and stationary phase (data not shown).  These observations imply 
that mastoparan exhibits a kinetically rapid and direct mechanism of bacterial 
killing and it is effective at killing bacteria in both log and stationary phase. 
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Figure 6: Mastoparan is effective against stationary phase bacteria.  P. 
aeruginosa was incubated in the presence of mastoparan at the noted 
concentration.  (A) Optical density and (B) colony-forming unit measurement of 
bacterial growth inhibition using a stationary phase culture of P. aeruginosa.  Red 
line demonstrates when antibacterial was added.  This data shows that 
mastoparan rapidly kills stationary phase bacteria.  The same experiment was 
performed using E. coli and S. aureus with similar results (data not shown). 
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2.3.7 Mastoparan is a mast cell activator in vitro and in vivo 
 Given the ability of mastoparan to activate mast cells [239], we 
hypothesized that along with its antibacterial activity, mastoparan may function 
as an immunomodulatory molecule.  To explore the capabilities of mastoparan to 
function as an immune stimulatory molecule, we first sought to confirm its 
ability to cause mast cell degranulation in vitro and in vivo.  Consistent with 
previously reported studies [239, 260, 303-305], we observed that mastoparan is a 
mast cell activator in vitro.  Following incubation of mouse bone marrow derived 
mast cells in the presence of varying concentrations of mastoparan, we found 
that mastoparan caused significant mast cell degranulation, in a dose-dependent 
manner, between a concentration of 5 to 80 uM (Figure 7). 
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Figure 7: Mastoparan is an in vitro mast cell activator.  Mouse bone marrow 
derived mast cells cultured from the femurs of C57BL/6 mice were incubated in 
the presence of various concentrations of mastoparan.  Mastoparan causes 
significant mast cell degranulation at concentrations between 5 to 80 µM.  
Experiment performed by Joseph Oniyah. 
Having confirmed its ability to activate mast cell in vitro, we then sought 
to demonstrate the in vivo mast cell stimulation activity of mastoparan.  In order 
to investigate the capacity of mastoparan to cause mast cell degranulation in vivo, 
mastoparan was injected into the peritoneum of mice.  We preferentially chose 
the peritoneum as the body site to investigate as it is a contained environment, 
which allows for convenient isolation of resident mast cells and recruited 
immune cells from the lavage.   
After intraperitoneal administration of mastoparan, peritoneal contents 
were collected at varying time points up to 24 hours after treatment.  Cells were 
fixed to a slide and stained with toluidine blue, a dye that selectively stains mast 
 83 
cell granules.  We observed that mastoparan displays mast cell degranulation 
beginning at the 1 hour after treatment time point and peaking at 12 hours after 
treatment (Figure 8A).  As shown in Figure 8A, following the 12 hour time point, 
mast cell degranulation had decreased at the 24 hour time point.  This 
observation suggests that after the 12  hour time point, the mast cells had either 
replaced their original granules or that this decrease was due to the migration of 
mast cells out of the peritoneum considering that there were fewer visible mast 
cells present in the field of view during this time frame (data not shown).   
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Figure 8: Mastoparan is a potent mast cell activator in vivo.  (A) Mastoparan 
was injected into the peritoneum of mice and peritoneal lavage samples were 
collected and assayed for microscopic viewing of the mast cells present at the site 
of injection.  Mastoparan causes mast cell degranulation peaking at 12 hours after 
treatment.  The results represented in Figure 8A are from experiments performed 
by Joseph Oniyah.  (B) The mesentery of the mice were also collected and stained 
with avidin FITC.  Top two panels are representative of mesenteric mast cells 
from control mice, which display a clear cell boundary and abundant 
cytoplasmic granules.  Bottom two panels represent mesenteric mast cells from 
mice treated with mastoparan, which have extruded and dispersed granules.  
Mastoparan elicited visual degranulation of mesentery mast cells.   
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To further investigate in vivo mast cell degranulation, we examined tissue-
associated mast cells in the mesentery of mice following intraperitoneal 
administration of mastoparan.  We collected mouse mesentery samples from 
C57BL/6 mice treated with mastoparan and stained them with avidin FITC, 
which binds selectively and distinctly to mast cell granules.  As shown in Figure 
8B, mastoparan elicited mast cell degranulation in the mesentery of mice.  The 
mesentery of control mice (Figure 8B, top panels) treated with PBS revealed 
inactivated mesenteric mast cells that were visualized as tight granulated cells.  
In contrast, the mesentery of mice treated with mastoparan (Figure 8B, bottom 
panels) exhibited degranulated mast cells with dispersed granules around 
activated mast cells.  Together, these data suggest that mastoparan is highly 
effective at causing dose-dependent mast cell degranulation in vivo and is 
therefore a potential immunostimulatory molecule. 
2.3.8 Mastoparan treatment elicits the recruitment of neutrophils 
 Activated mast cells produce chemotactic factors that can modulate host 
innate immune response via the recruitment of pathogen clearing immune cells 
such as natural killer cells and neutrophils.  Given the prominent role of mast 
cells in the immune response and having shown that mastoparan elicits 
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activation of mast cells in vivo, we hypothesized that this mastoparan elicited 
mast cell activation leads to increased recruitment of immune cells, such as 
neutrophils, to the site of treatment.  To test this hypothesis and further 
investigate the potential of mastoparan to serve as an immunomodulatory 
molecule, we measured the amount of myeloperoxidase (MPO), a neutrophil 
marker enzyme, found in peritoneal lavage samples collected from mice treated 
with varying dosages of mastoparan.  Mastoparan demonstrated dose-
dependent neutrophil recruitment (Figure 9A) similar to the response displayed 
in relation to its in vivo mast cell activation (Figure 8). 
Furthermore, we explored the timing of neutrophil recruitment elicited by 
mastoparan by evaluating the MPO activity of peritoneal lavage samples of mice 
treated with mastoparan (50 µg) at different time intervals.  We found that 
mastoparan elicited the recruitment of neutrophils to the peritoneum beginning 
at six hours after treatment and peaking at twelve hours after treatment (Figure 
9B).  These studies suggest that mastoparan causes recruitment of neutrophils to 
the site of injection.  Additionally, these data strongly suggest that this 
neutrophil recruitment is caused by the mastoparan induced mast cell 
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degranulation at this site since the neutrophil recruitment response parallels the 
mast cell degranulation response. 
 
Figure 9: Mastoparan elicits the recruitment of neutrophils.  (A) Various 
concentrations of mastoparan were injected into the peritoneum of mice and 
peritoneal lavage samples were assayed for MPO.  Mastoparan causes significant 
neutrophil recruitment at concentrations between 10 to 100 µM.  (B) At various 
time points, mice injected peritoneally with mastoparan (50 µg) were sacrificed 
and peritoneal lavage samples were assayed for MPO Activity.  Instillation of 
mastoparan into the peritoneal cavity causes neutrophil recruitment into the site 
of injection.  Experiments performed by Joseph Oniyah. 
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2.3.9 Mastoparan is effective as a topical antibacterial agent utilizing 
its dual action direct antibacterial and immunomodulatory activities 
Globally there is an increase in bacterial skin infections, especially those 
caused by multidrug resistant bacteria.  There is a lack of effective treatments 
against these infections, particularly treatments to eradicate infections consisting 
of stationary phase bacteria.  We sought to determine the efficacy of mastoparan 
as a topical antibacterial treatment against skin infections utilizing a mouse skin 
colonization and infection model.  We employed a skin colonization assay to test 
the ability of mastoparan as a topical antibacterial treatment against both log and 
stationary phase bacteria applied to the shaved intact skin of mice.  For 
comparison, we used Neosporin a common topical antimicrobial agent whose 
active ingredients are neomycin, polymyxin, and bacitracin.  The results of this 
experiment are summarized in Figure 10, which shows that mastoparan 
significantly reduced the number of colony-forming units recovered from the 
skin of mice colonized by log phase S. aureus with a 95% reduction and 
stationary phase S. aureus with a 99% reduction.  In contrast, Neosporin was 
effective at reducing the number of colony-forming units recovered from the skin 
of mice colonized with log phase bacteria by 85%; however, it showed no activity 
against stationary phase bacteria.   
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Figure 10: Mastoparan reduces the number of colony forming units (CFUs) in a 
superficial skin S. aureus colonization model.  Enumeration of S. aureus 
recovered from mice following a superficial skin infection.  The backs of mice 
were shaved and hair was removed by chemical depilation.  (A) Log or (B) 
stationary phase bacteria were applied to the backs of the mice, and then treated 
20 minutes later with mastoparan or Neosporin.  Skin tissue was excised with an 
8mm punch biopsy, homogenized, and CFU counts determined via agar plating.  
This data demonstrates that mastoparan is able to significantly reduce the 
number of colony-forming units present with both log and stationary phase 
bacteria.  Statistical analyses were performed using the unpaired two-tailed 
Student’s t-test.  *P < 0.05, **P<0.0005 
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This data agrees with the studies presented by other researchers [46-49, 269, 270] 
demonstrating that most antibiotics in current use are unable to significantly 
affect stationary phase bacteria typically encountered in clinical infections.  
Importantly, we found that mastoparan is a potent topical antibacterial agent 
exhibiting activity against both log and stationary phase bacteria.   
Next, we developed an intradermal skin bacterial infection model, where 
we injected S. aureus (108) directly under the upper epidermal layer of the backs 
of shaved mice.  Mastoparan (10 µg) was infused in a vehicle of olive oil and 
DMSO to enable the drug to stay in place on the skin and to allow for 
transdermal migration.  Mastoparan was applied topically (with the aid of a 
pipette tip to spread it across the infected area) to the site of infection every 12 
hours with the first treatment taking place 12 hours after infection.  As shown in 
Figure 11, mastoparan reduced the bacterial load of the infection by up to 98% (in 
comparison to the vehicle control of olive oil/DMSO).   
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Figure 11: Mastoparan reduces the number of colony forming units (CFUs) of 
S. aureus recovered from excised skin lesions in an intradermal skin infection 
model.  Enumeration of S. aureus recovered from mice (n = 8) treated with 
mastoparan or vehicle control (olive oil/DMSO) were sacrificed on days 1, 2, 3, 5, 
10, and 15 following an intradermal skin infection.  The backs of mice were 
shaved and hair was removed by chemical depilation.  To establish an 
intradermal skin infection the mice were injected subcutaneously with 100 μL of 
S. aureus (108) complexed to Cytodex beads as a carrier.  Mice were treated with 
mastoparan every 12 hours after infection (beginning at 12 hours after the 
bacteria were injected).  Statistical analyses were performed using the unpaired 
two-tailed Student’s t-test on log (10) transformed data.  *P < 0.05, **P<0.005 
 
Furthermore, we hypothesized that the ability of mastoparan to activate 
mast cells will allow it to be a more effective antibacterial agent through the 
recruitment of inflammatory cells (e.g., neutrophils) to enhance and increase host 
defense locally at the site of infection.  In order to test this hypothesis, we excised 
8mm punch biopsies of the skin at the site of infection and performed a MPO 
assay to determine neutrophil recruitment.  We found that mastoparan is able to 
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cause a significant increase in the number of neutrophils recruited to the site of 
infection at the day 5 and day 10 time points (Figure 12).  Overall, we have 
demonstrated that mastoparan is able to cause a significant reduction in the 
number of colony-forming units recovered in a colonization and infection model 
as well as increased neutrophil recruitment.  Taken together, this data for the 
first time implicates mastoparan as a highly effective topical agent against 
bacterial skin infections having both direct antibacterial activity and increased 
immune stimulatory activity. 
 
Figure 12: Mastoparan causes significant increase in neutrophil recruitment 
during a S. aureus intradermal skin infection model.  MPO activity of mice (n = 
8) treated with mastoparan or vehicle control (olive oil/DMSO) every 12 hours 
after infection (beginning at 12 hours after the bacteria were injected).  Treatment 
with mastoparan caused an increase in the number of neutrophils recruited to 
the site of infection at the day 5 and 10 time points.  Statistical analyses were 
performed using the unpaired two-tailed Student’s t-test.  *P < 0.05 
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2.3.10 Mastoparan does not exhibit dermal toxicity 
 To further elucidate the potential of mastoparan to serve as a topical 
antibacterial agent, we studied the possibility of mastoparan elicited dermal 
toxicity.  To investigate mastoparan for potential dermal toxicity, mice were 
treated with mastoparan for 14 days via topical or intradermal application.  We 
tested for dermal toxicity using a mastoparan dose of 50 µg and 100 µg, which 
represents 5 and 10 times the dosage used in the skin colonization and infection 
studies.  Throughout the 14 days of administration, no treatment related adverse 
events were observed such as change in body weight, body temperature, 
observable behavior (e.g., distress, discomfort, and activity level), irritation, 
mutilation of the procedure site, or inflammation (data not shown).  These 
observations imply that mastoparan does not exhibit dermal toxicity at a dose up 
to 100 µg. 
2.3.11 Mastoparan promotes mast cell-dependent wound healing in 
mice 
Interestingly, during our observation of skin lesions in the intradermal 
skin infection assay, we noticed that mastoparan treatment caused significant 
morphological changes in the appearance of the skin lesion.  We found that 
mastoparan treated mice exhibited decreased lesion size implying faster healing.  
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Thus in addition to reducing bacterial numbers and increasing neutrophil 
recruitment mastoparan was evoking a third component of the immune defense, 
wound healing.  Figure 13 shows pictorial representations of the morphological 
changes observed including progressed wound healing and scab formation with 
more advanced skin maturation and remodeling as the scab has begun to 
separate from the underlying tissue (inner circle of dried tissue at wound edges).  
These visual differences in lesion size between mastoparan treated mice and 
control mice, was confirmed by quantitative lesion size measurements (vertical 
and perpendicular diameters) which showed that treatment with mastoparan led 
to an up to 79% reduction in the size of the lesions (Figure 14). 
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Figure 13: Pictorial representation of mice treated with mastoparan during a S. 
aureus intradermal skin infection.  The backs of mice (n = 4-28) were shaved and 
hair was removed by chemical depilation.  To establish an intradermal skin 
infection, the mice were injected intradermally with 100μL of S. aureus (108) 
complexed to Cytodex beads as a carrier.  Mice were treated with mastoparan 
every 12 hours after infection.  Pictorial representation of skin lesions of mice 
treated with Olive Oil/DMSO (vehicle control) as compared to mice treated with 
Neosporin or mastoparan.  Mastoparan treated mice have progressed wound 
healing and accelerated wound closure in comparison to control and Neosporin 
treated mice.  The pictures shown are representative of all studies in which 
similar differences were observed.   
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Figure 14: Mastoparan significantly reduces the size of lesions formed during a 
S. aureus intradermal skin infection.  The backs of mice (n = 4-28) were shaved 
and hair was removed by chemical depilation.  To establish an intradermal skin 
infection, the mice were injected intradermally with 100μL of S. aureus (108) 
complexed to Cytodex beads as a carrier.  Mice were treated with mastoparan 
every 12 hours after infection.  Lesion sizes were measured daily.  Mastoparan 
treated mice have markedly smaller lesions as compared to untreated mice in a S. 
aureus skin bacterial infection model.  Statistical analyses were performed using 
the unpaired two-tailed Student’s t-test.  *P < 0.05, ** P <0.005 (Mastoparan 
compared to vehicle control: DMSO/Olive Oil.  +P<0.05, ++P<0.005 (Mastoparan 
compared to Neosporin). 
To highlight the wound healing actions of mastoparan and distinguish them 
from its antibacterial actions, we compared these results to those obtained with 
Neosporin treated mice.  We found that Neosporin, in spite of its known 
antibacterial actions, did not cause significant improvement in lesion size.  
Indeed, at certain time points the lesion size measurements for Neosporin treated 
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mice were greater than the lesion size measurements for the control mice.  These 
observations suggest that the topical instillation of mastoparan at the site of 
infection increases bacterial clearance, enhances neutrophil recruitment, and 
promotes wound healing. 
The enhanced wound healing finding was an unexpected result so we 
sought to investigate if this activity was linked to mastoparan elicited activation 
of mast cells.  It is noteworthy that mast cells have previously been implicated in 
the healing of skin wounds [306-308].  Mast cells have been reported to accelerate 
wound closure and their release of histamine is functionally important for the 
healing of cutaneous wounds [309, 310].  Based on this, we hypothesized that 
mastoparan elicited mast cell activation could have contributed to the observed 
acceleration in wound healing.  To test this notion we reasoned that mastoparan 
treatment of intradermal skin infections in mast cell deficient (Wsh/Wsh) mice 
would predictably show no obvious enhancement of wounds when compared to 
control mice.  Utilizing the intradermal skin infection model, we undertook this 
experiment and compared lesion sizes following S. aureus infection of 
mastoparan treated and untreated mast cell deficient mice.  We found that in the 
absence of mast cells, there appeared to be no discernible difference in the lesion 
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size of mice treated with mastoparan in comparison to the control (Figure 15).  
This data suggests that the observed promotion of wound healing by mastoparan 
is mast cell dependent. 
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Figure 15: Mast cells are required for the promotion of wound healing by 
mastoparan.  The backs of mast cell deficient (Wsh/Wsh) mice (n = 6) were shaved 
and hair was removed by chemical depilation.  They were injected intradermally 
with 100μL of S. aureus (108) complexed to Cytodex beads as a carrier.  Mice were 
treated with mastoparan every 12 hours after infection.  Lesion sizes were 
measured daily.  This data demonstrates that there is no significant difference in 
the lesion size of mice treated with mastoparan in comparison to the control.   
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2.4 Discussion 
Antimicrobial peptides are a group of small peptides found amongst 
almost every class of life.  These peptides typically have a potent and direct 
killing mechanism of action.  Another group of peptides, innate immune 
modulators are an important component of host immune defenses via 
immunostimulatory activities including chemoattraction of immune cells and 
promotion of angiogenesis and wound healing.  Together, antimicrobial and 
immune modulating peptides represent a new field of exploration for successful 
anti-infective therapies.  Peptides with both abilities, antibacterial and 
immunomodulatory, have the capacity to be novel therapeutics against bacterial 
infections.  The primary aim of this study was to demonstrate the antibacterial 
and mast cell activation capabilities of mastoparan and to show that these 
properties can be harnessed for the treatment of bacterial skin infections.  In this 
study, we have successfully shown the dual action exhibited by a wasp venom 
peptide through its ability to stimulate the innate immune mechanisms and 
directly kill bacteria in a bactericidal manner (Figure 16).  Furthermore, our 
observations strongly support the potential of mastoparan to promote epithelial 
wound healing. 
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Mast cells are preferentially located at the host-environment interface 
(e.g., skin and mucosal sites).  They are activated by and can detect bacteria and 
recruit inflammatory cells such as neutrophils to the site of infection, thereby 
contributing to the innate immune response.  Previous studies have shown that 
mast cells are functionally important in the induction of the host defense 
response during bacterial skin infections (reviewed in [263]).  Mastoparan was 
initially discovered based on its ability to activate mast cells in vitro [239].  Here 
we have demonstrated that mastoparan is a potent mast cell activator (Figure 8), 
and stimulates the recruitment of neutrophils in vivo (Figure 9).  Furthermore, we 
found that mice infected with bacteria and treated with mastoparan, demonstrate 
increased neutrophil recruitment (Figure 12) along with increased bacterial 
clearance (Figure 10and 11). 
Several of the peptides in the mastoparan family have been shown to 
exhibit antibacterial activity in vitro [238, 239, 255, 286].  Our studies complement 
and extended these works by showing that mastoparan has antibacterial activity 
against a broad-spectrum of bacteria, both Gram-negative and Gram-positive 
strains (Table 2) and has a broader range of action and efficacy in relation to 
some marketed antibiotics (Table 3).  Additionally, mastoparan has activity 
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against multidrug resistant bacteria (Table 4), which has become a growing 
global concern.   
Our studies examining the mechanism of action exhibited by mastoparan 
show that it achieves its bactericidal effect via increased membrane permeability 
allowing efflux of cytoplasmic material (Figure 2 and 3).  Furthermore, 
mastoparan exhibits a rapid mechanism of bacteria growth inhibition and has the 
ability to reduce bacteria colony forming units in less than 30 minutes, 
suggesting that has a direct killing method (Figure 6).  Mastoparan is also able to 
significantly reduce bacteria numbers in both stationary and log phase bacterial 
cultures (Figure 6).  This is in contrast to a method of inhibition that requires cell 
growth and replication such as that shown by marketed antibiotics.  
Mastoparan’s rapid mechanism of killing combined with the broad-spectrum of 
action and efficacy against both stationary and log phase bacteria, leads us to 
conclude that mastoparan is an excellent candidate for development as a 
therapeutic agent 
A particularly striking finding from our work is that mastoparan treated 
mice showed a significant reduction in the lesion sizes of mice infected with S. 
aureus, suggesting increased wound healing.  Natural wound healing is a 
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dynamic process involving several different cell types and soluble mediators.  
These processes include inflammation, tissue remodeling, cell proliferation, and 
migration [311-315].  A key component of the inflammation process includes the 
recruitment of neutrophils to the site of injury [316-318].  As stated previously, 
our data demonstrates that mastoparan increases neutrophil recruitment and 
mast cell degranulation.  We have also shown that mice treated with mastoparan 
have significantly smaller lesions as compared to untreated mice suggesting that 
mastoparan, through the activation of mast cells and the recruitment of 
neutrophils, may modulate tissue responsiveness and accelerated wound 
healing. 
  Mastoparan shows significant and vast potential for use as a therapeutic 
due to its demonstrated effectiveness against bacterial skin infections.  Here, we 
have for the first time successfully illustrated the dual ability of mastoparan to 
stimulate the immune system through the activation of mast cells and it has 
direct antibacterial activity via membrane permeabilization.  Together, these 
abilities contribute to its effectiveness against bacterial skin infections and makes 
it an excellent target as the next line of antimicrobials. 
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Figure 16: Summary of the biological activities of mastoparan. 
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Chapter 3: Perspectives and Conclusion 
Bacterial infections are a major cause of death, disease, and increasing 
financial burden on the health care industry.  Due to the growing threat of 
multidrug resistant bacteria, previously confined to health care settings (e.g., 
hospitals and clinics) but now seen more frequently in the community, bacterial 
infections are becoming even more difficult to treat.  Multidrug resistance is now 
common and the increased accumulation of these pathogenic bacteria has greatly 
limited therapeutic options.  In the pharmaceutical industry, antimicrobial drugs 
represent the third most profitable class of drugs behind those dealing with 
central nervous and cardiovascular systems [319].  However, there has been a 
lapse in the development of innovative antibacterial drugs in the past decade.  
Antimicrobial agents found in wasp venom have recently gained attention as 
novel natural products capable of combating multidrug resistant pathogens.   
The work presented here provides experimental data that broadens our 
understanding of the potential utility of the wasp venom peptide, mastoparan, as 
an in vivo antibacterial therapeutic employing mouse models of infection.  Prior 
contributions to this field have focused exclusively on demonstrating the general 
ability of mastoparan to act as an antibacterial or mast cell activator in vitro [239, 
255, 259].  The current study has confirmed the ability of mastoparan to work 
 106 
against natural pathogens and shown its efficacy against multidrug resistant 
bacteria, while also determining the in vivo biological significance of mastoparan.  
This dissertation investigates the ability of mastoparan to both directly kill 
bacterial pathogens and stimulate the natural host immune system via mast cell 
activation.  Immunomodulatory therapy is a novel anti-infective approach that 
may enable us to selectively enhance the host immune response to infection.  
Due to the growing evidence that mast cells orchestrate early innate and 
acquired immune responses to infection, we believe that the bactericidal activity 
of mastoparan combined with its immunomodulatory activity via mast cell 
activation make it an effective but largely overlooked therapeutic.   
3.1 Broad-spectrum antibacterial and immunomodulatory 
activity exhibited by mastoparan 
The development of new antimicrobial agents to combat the growing 
incidence of bacterial infections and bacterial resistance is a primary global 
concern.  Most antimicrobial agents in the pipeline for development have a 
limited range of action and are unable to work against stationary phase bacteria.  
Here, we have demonstrated that mastoparan is effective against a wide range of 
Gram-negative, Gram-positive, and clinically resistant bacterial pathogens.  The 
data presented here demonstrating that mastoparan is effective against 
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multidrug resistant bacteria in vitro suggests its potential utility against these 
pathogens in vivo.  Further studies to determine if mastoparan is effective against 
these resistant pathogens in vivo are necessary.  Due to the increased need for 
new anti-infective therapies, further studies investigating the utility of 
mastoparan against a range of different microorganisms (e.g., viruses, parasites, 
and fungi) may be useful since previous studies have shown that other 
antimicrobial peptides similar to mastoparan also have antiviral, antifungal, 
and/or anti-parasitic activities as well [174, 175, 226, 320, 321]. 
We have presented multiple lines of experimental evidence to show that 
mastoparan utilizes a mechanism of action that involves interaction with the 
bacterial cell membrane similar to other antimicrobial peptides [174, 177-179].  
Here, we show that mastoparan interacts with the cell membrane via a 
mechanism that causes structural perturbations such as blebs and pores, leading 
to the release of bacterial cytosolic contents.  Our experimental data 
demonstrates a rapid (in many instances less than 15 minutes) mechanism of 
action that significantly reduces the number of colony-forming units.  
Interestingly this reduction in colony-forming units occurs even in the presence 
of stationary phase (non-multiplying) bacterial cultures.  This suggests that the 
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main mechanism of action for mastoparan is via an interaction with the bacterial 
cell membrane. 
Previous studies have revealed that some antimicrobial peptides may also 
have a mechanism of action that includes an intracellular target in addition to 
their interaction with the cell membrane [182-188, 322, 323].  Stationary phase 
bacteria require minimal cellular metabolic processes such as DNA/RNA 
synthesis and protein synthesis.  Most intracellular targets hinder such 
components of cellular physiology, and therefore if mastoparan is able to reduce 
colony-forming units for stationary phase bacteria, this suggests that it has a 
killing mechanism of action that does not require bacterial growth and 
reproduction.  Future studies to determine if mastoparan has the ability to utilize 
an intracellular target could be beneficial. 
Although we have not noticed any resistance development, additional 
benefit can also be gained from an investigation of mechanisms that bacteria 
utilize to develop resistance to mastoparan.  To this end, given that antimicrobial 
peptides are a component of wasp venom that aid in combating invading 
microorganisms, we can utilize this information to search for microorganisms 
that have been able to successfully circumvent this natural system in wasps to 
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help reveal information about the type of systems that bacteria can exploit to 
develop resistance.  This will allow us to more efficiently devise methods to 
reduce the development of resistance with strategies such as combination 
therapy. 
Immune stimulatory molecules have an enormous amount of potential 
utility as antimicrobial agents, due to their ability to boost the natural host 
response (e.g., mast cell activation and neutrophil recruitment) to infections.  
There are several natural molecules such as small peptides and CpG DNA that 
have been shown to stimulate the immune response to control infection; 
therefore, it may be possible to use similar molecules to boost the natural 
immune response to infection [205, 324-326].  Our studies, along with the work of 
other investigators, have shown that mastoparan is a potent mast cell activator in 
vitro [239]. 
Mast cells are specialized, granulated innate immune cells involved in 
bacterial clearance.  Mast cells assist in the clearance of pathogens (i.e., parasites, 
bacteria, and viruses) and are able to directly and indirectly recognize pathogens 
including those bound by host defense proteins.  They can rapidly degranulate, 
releasing pre-stored inflammatory mediators, and can synthesize de novo 
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mediators and inflammatory cytokines.  Mast cells have the ability to directly kill 
bacteria through phagocytic actions and the release of antibacterial peptides (e.g., 
cathelicidins) of their own [257, 327-335].  However, the majority of their 
antibacterial activity is due to their ability to mediate the recruitment of other 
immune cells such as neutrophils and antigen presenting cells to the site of 
infection [332, 336-339].  The studies presented here have demonstrated that 
instillation of mastoparan in the peritoneal cavity causes mast cell activation and 
neutrophil recruitment.  This suggests that mastoparan is a potent 
immunomodulatory agent in vivo.  In future studies, we hope to determine 
whether mast cells are the only immunomodulatory cell type activated by 
mastoparan. 
Mast cells are not only known to play a role in innate immunity but they 
are also known to contribute to acquired immunity leading to long-lasting 
recognition of pathogens, which increases eradication and clearance speed 
during subsequent infection.  Studies have shown that mast cells facilitate the 
acquired immune response via mechanisms such as the secretion of products, 
antigen presentation, and the mobilization of effector cells (reviewed in [332], 
[339]).  In future studies, we hope to confirm that mastoparan induced mast cell 
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activation enhances the acquired immune response to infection in addition to the 
increase in innate immunity that we have demonstrated.    
3.2 Mastoparan is a highly effective therapeutic agent against 
bacterial skin infections 
Skin and soft-tissue infections account for more than 14 million outpatient 
visits in the United States each year and have an estimated prevalence of 7-10% 
among all hospitalized individuals [266, 267].  Furthermore, skin infections are 
the third most common diagnosis in emergency care settings, behind chest pain 
and asthma.  These infections are becoming more complicated due to the 
emergence of multidrug resistant organisms such as methicillin-resistant 
Staphylococcus aureus (MRSA) [340, 341].  As a complex organ, human skin has 
many natural protective mechanisms to ensure protection from microbial attack.  
However, when the skin barrier is breached via damage such as burns, cuts, or 
wounds infection can occur.  Here, we have shown that topical application of 
mastoparan is able to significantly reduce the number of colony-forming units 
recovered from a skin infection model in mice. 
As discussed, we believe that the ability of mastoparan to serve as an 
immunomodulatory stimulator via mast cell activation leading to neutrophil 
recruitment, in addition to its direct antibacterial capabilities, makes it a more 
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powerful and effective topical antimicrobial agent.  Having determined that 
mastoparan is able to activate mast cells and stimulate neutrophil recruitment in 
the absence of infection, we sought to determine if these same capabilities were 
present or enhanced during bacterial skin infections.  Previous studies have 
shown that the activation of mast cells and the recruitment of neutrophils are 
required for the clearance of bacterial skin infections in mice [342].  We have 
shown that mice treated with mastoparan have increased neutrophil recruitment 
in the presence of a bacterial skin infection.  This is strong evidence that the 
immune stimulatory activity of mastoparan may promote and enhance its 
antibacterial activity. 
In future studies, we hope to determine how mast cells modulate the 
enhanced antibacterial activity that we observed and if there are other cell types 
involved.  Additionally, information determining whether the observed increase 
in neutrophil recruitment is due to direct activation of mast cells or to increased 
inflammation caused by the direct killing of bacteria by mastoparan would give 
further insight into distinguishing the contribution of the antibacterial and 
immunomodulatory activities of mastoparan.  The data presented here 
demonstrating that mastoparan is effective against multidrug resistant bacteria in 
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vitro suggests its potential utility against these pathogens in vivo.  Further studies 
to determine if mastoparan is effective against these resistant pathogens in vivo 
are necessary. 
Most antimicrobial peptides have demonstrated limited in vivo capabilities 
due to host toxicity, protease degradation, and absorption within the body due to 
their small size and high charge [174, 175, 192, 193].  Thus, their therapeutic 
utility is typically limited to topical applications or direct injection into the site of 
infection.  We have presented multiple lines of experimental evidence 
demonstrating that there is no detectable toxic effect with mastoparan at a 
dosage of up to 100 µg (10 times the amount used in our skin infection model).  
In future studies, we hope to determine whether mastoparan can be used in a 
systemic model (parenteral and oral) of infection.  Systemic use may require that 
we make chemical modifications to the structure of mastoparan (e.g., produce a 
peptidomimetic equivalent or extend its length via attachment of polyethylene 
glycol) in order to reduce the likelihood of protease degradation or minimize 
cellular absorption.  Additionally, future studies to determine an appropriate 
topical formulation (many topical ointments contain a petroleum jelly base) for 
mastoparan are necessary along with studies to determine its stability in such a 
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base formulation.  Recent studies have demonstrated the effectiveness of 
incorporating antimicrobial peptides into materials such as polyelectrolyte 
multilayer films, formulation into liposomes or nanoparticles, and freeze-dried 
antimicrobial wafers to improve stability, permit prolonged drug release and 
extended application [190, 321, 343-345]. 
3.3 Mastoparan promotes wound healing 
Treatment of chronic wounds costs over 25 billion dollars annually and 
more than 6.5 million people are affected by chronic wounds in the United States 
[346, 347].  The number of individuals affected by these wounds and the amount 
of associated health-care costs is steadily increasing due to such factors as the 
drastic increase in our elderly population and a global increase in the number of 
individuals suffering from diabetes and obesity [348].  Wound infections have 
led to almost 100,000 leg amputations, which severely compromise quality of life 
and increased mortality [348, 349].  Additional concerns surround post-surgical 
wound care (more than 34 million surgeries are performed each year), acute 
emergency wound care, and skin scarring [348, 350].  Wounds (caused by burns, 
surgery, etc.) pose significant global health, economic, and social problems 
 115 
presenting the need for the development of new approaches for the treatment of 
these wounds. 
Prior contributions to this field have demonstrated the potential of small 
peptides to promote wound healing and angiogenesis due to their ability to 
mediate innate and acquired immune responses.  Human cathelicidins 
(hCAP18/LL-37) have been shown to be expressed after wounding and activate 
epidermal cells and fibroblasts as chemoattractants for wound healing 
components such as macrophages, fibroblasts, and keratinocytes  [351-353].  
Similar peptides have also been shown to inhibit tissue injury through the 
inhibition of proteases [205].  In attempting to understand the contribution of 
mastoparan to the reduction of colony-forming units in a bacterial skin infection 
model, we have also addressed its ability to promote wound healing.  In doing 
so, we found that treatment of wounds with mastoparan resulted in up to a 79% 
reduction in lesion size.  We have also shown that the promotion of wound 
healing by mastoparan is mast cell dependent via studies utilizing mast cell 
deficient mice (KitW-sh/KitW-sh).  In future studies, we hope to further elucidate the 
role that mast cell activation plays in this promotion of wound healing, especially 
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in the absence of infection, which will allow us to gain further insight into how 
mastoparan facilitates wound healing.   
3.4 Conclusions 
There is a need for new therapies to treat bacterial infections especially 
infections involving multidrug resistant bacteria for which the incidence of 
resistance is steadily increasing, mostly due to antibiotic misuse or overuse.  One 
major area for future development to combat these infections is the use of 
antimicrobial peptides that promote immunomodulatory activity.  These 
molecules have the broad potential not only to be utilized as an anti-infective 
agent but also as adjuncts to support other treatments including wound healing, 
vaccine adjuvants, and anticancer drugs.  Mastoparan is a potential anti-infective 
with a broad-spectrum of activity that includes efficacy against resistant bacteria 
(e.g., MRSA, ESBL E.coli, and ESBL K. pneumonia).  In addition to its strong 
antibacterial properties, it is also an effective immunomodulatory molecule, 
which increases its versatility and overall efficacy.  This work makes important 
contributions to the general understanding of antimicrobial peptides and 
immune stimulatory molecules and their potential as anti-infective agents.  The 
use of immune stimulatory molecules is a novel approach to combat bacterial 
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infections and we can exploit the immunomodulatory properties of these 
molecules to create more effective anti-infective therapies.  Furthermore, 
increased understanding of the fundamental processes involved will present new 
approaches and innovative technologies for managing immune responses in a 
clinical setting.  
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